13th Conference of the
International Society of Travel Medicine

Maastricht, The Netherlands
Maastricht Exposition and Conference Center (MECC)
19-23 May 2013

Early Registration: 31 December 2012
Abstract Submission: 17 January 2013

www.ISTM.org
Promoting healthy travel worldwide
Executive Board
President
Alan J. Magill, United States of America
President-Elect
Fiona Genasi, United Kingdom
Past-President
Frank von Sonnenburg, Germany
Counselor
Eric Caumes, France
Counselor
Lin H. Chen, United States of America
Counselor
David R. Shlim, United States of America
Counselor
Annelies Wilder-Smith, Singapore
Secretary/Treasurer
David O. Freedman, United States of America

Publication Editors
Editor, Journal of Travel Medicine
Robert Steffen, Switzerland
NewsShare Editor
Peter Leggat, Australia
ISTM Web Editor
Hans D. Nothdurft, Germany

Standing Committee Chairs
Certificate Of Knowledge Exam
Kenneth R. Dardick, United States of America
Continuing Professional Development
Phyllis Kozarsky, United States of America
Development Committee
Robert Steffen, Switzerland
Liaison
Michele Barry, United States of America
Professional Education
Charles D. Ericsson, United States of America
Publications
Anne E. McCarthy, Canada
Research & Awards

Professional Group Chairs
Nursing
Jane Chiodini, United Kingdom
Pharmacy Chair
Larry Goodyer, United Kingdom
Pharmacy Chair-Elect
Jeffery A. Goad, United States of America

Interest Group Chairs
Destination Community Support
Assunta Marcolongo, Canada
Migrant and Refugee Health
Elizabeth Barnett, United States of America
Pediatrics
Philip R. Fischer, United States of America
Psychological Health of Travelers
Ted Lankester, United Kingdom

Executive Director
Diane L. Nickolson, United States of America

International Society of Travel Medicine
315 W. Ponce de Leon Ave.
Suite 245
Decatur, GA 30030 USA
Phone: +1.404.373.8282 • Fax: +1.404.373.8283 • E-mail: istm@istm.org
Program and Book of Abstracts

Table of Contents

Welcome Messages 3
Committees 5
Acknowledgements 6
Important Information 7
Floor Plan for John B. Hynes Veterans Memorial Convention Center 9
Guide to Session Format 11
Faculty Disclosures 13
Opening Ceremony 14
Scientific Program Schedule 15
Exhibitor’s Index 45
Exhibition Floor Plan 46
Exhibitors 47
Message from the ISTM President and Local Organizing Committee Chair

On behalf of the International Society of Travel Medicine and the Local Organizing Committee, we are delighted to welcome you to Boston, Massachusetts, USA for the 12th Conference and 20th anniversary celebration of the International Society of Travel Medicine. We hope you will enjoy Boston, one of the oldest and most historical cities in the United States of America, and which is considered the economic and cultural hub of New England.

Although all CISTMs are special events, CISTM12 is a milestone for the Society as it marks the 20th anniversary of the ISTM. It was during the first Conference of International Travel Medicine in 1988 that close to 500 travel medicine professionals gathered and decided to launch an international society focused solely on travel medicine. ISTM was officially established during the second Conference of International Travel Medicine in 1991. ISTM has now grown to over 2,500 members in 75 countries and is the largest organization of professionals dedicated to the advancement of the specialty of travel medicine. Our CISTMs are really outstanding opportunities that occur only every 2 years for all the world’s travel medicine practitioners to come together to share experiences, enjoy a collegial environment, and do a bit of traveling themselves.

The biennial ISTM conferences are established as the leading venue for the practice and science of the discipline of travel medicine. We wish to take this opportunity to thank all of the participating presenters and Scientific Committee whose hard work enabled the planning of a truly informative and dynamic program, from which all attendees are sure to benefit. Educational formats include plenaries, symposia, a debate, workshops and meet the history, meet the experts, case of the day and free communication sessions.

During the conference, meetings of the ISTM’s committees and groups have been scheduled. While these will be of special interest to members, delegates wishing to attend in order to become more actively involved are also welcome. ISTM leaders who can be identified by ribbons on their delegate badges would be delighted to answer any questions you have regarding the society and activities of the ISTM. In addition, we encourage you to visit the ISTM booth in the exhibition hall for queries on membership, society activities, resources, literature and upcoming meetings.

We welcome you to the CISTM12 and to Boston, one of the oldest cities in the United States of America, founded in 1630. It is best explored on foot, and walking the streets of Boston you will find historical sites as well as unique neighborhoods, specialty shops and wonderful restaurants. While in Boston, we hope you will be find the time to walk the Freedom Trail, explore the Public Garden, visit Harvard Square, and try some of the many fine dining options.

Alan J. Magill
ISTM President

Davidson Hamer
Local Organizing Committee Chair
Dear Colleagues

On behalf of the Scientific Committee we would like to welcome you to Boston where you will be treated to a stimulating CISTM12 and enjoy the many activities and rich history that this wonderful New England city has to offer. The Organizing Committee has chosen a conveniently located state-of-the-art facility for the conference and has put together an exciting program of extra-curricular activities. We are fortunate to have confirmed many high profile and experienced speakers who will provide you with the most important and current news in the discipline of travel medicine. In addition, a large number of outstanding speakers and facilitators from the Boston area will participate and contribute their expertise and knowledge to the scientific program.

The Scientific Committee began planning CISTM12 immediately after the meeting wrapped up in Hungary. We met for the first time exactly one year ago in Boston to begin working on the scientific program. We have tried to develop a program that will be exciting and stimulating for all members of our Society with presentations that will cover the latest cutting edge information in travel medicine as well as topics and clinical challenges that travel practitioners routinely encounter in their daily practice. To develop this program we have carefully taken into account the feedback from ISTM members during the past CISTM meetings and hope we have created a broad-based program that will be delivered by many of the leading experts in the field. The response to our invitations to present at the conference has been very positive and very few colleagues have declined to participate.

In a second meeting near Lisbon in February 2011, we were pleased to be able to choose among more than 230 original submissions for the limited slots for free oral communications. We would like to acknowledge all the hard work of the contributors who submitted well-designed and creative original work. The high quality of the abstracts submitted, all of which were carefully read and assessed by at least five members of the Scientific Committee, resulted in an additional free communication session to accommodate and showcase your excellent work. Thus 47 contributions of our members will be presented as oral communications, giving a number of young colleagues their first opportunity to present to an international audience. Almost all the other abstracts will be presented as posters during the conference, thus providing a wide range of innovative work from around the globe.

We would like to thank all 30 colleagues of the Scientific Program Committee who did a wonderful job in submitting proposals for sessions and in working closely with us to evaluate the submitted abstracts in a transparent manner. Their input contributed to the breadth and richness of the topics and content of the plenaries, symposia and workshops chosen. We extend a special thanks to all members of the Society who contributed suggestions for the different sessions. We have tried our best to balance the selection of topics for this conference, emphasizing new ideas while providing ample coverage of general topics that – we are sure – you would like to hear the latest news about.

The membership is a great inspiration for the work of the Scientific Committee. Your contributions and thoughts are valuable to the Society. CISTM12 provides an opportunity for Travel Medicine providers to connect with old colleagues, make new contacts, exchange ideas, discuss controversial topics and not the least; to enjoy and have fun. We look forward to an exciting and thought-provoking conference with many opportunities to network and to keep up to date with what is happening in Travel Medicine. We look forward to seeing all of you in Boston.

Warm wishes,

Christoph Hatz
CISTM12 Scientific Chair

Mary Wilson
Co-Chair

Christina Greenaway
Associate Chair

Leo Visser
Associate Chair
CISTM12 Local Organizing Committee

Davidson Hamer  
Karen Avery  
Elizabeth Barnett  
Lin Chen  
Natasha Hochberg  
Laura Kogelman  
Rhonda Martin  
Maria D. Mileno  
Edward T. Ryan  
Suzy Sarfaty  
Mary E. Wilson  

United States of America - Chair  
United States of America  
United States of America  
United States of America  
United States of America  
United States of America  
United States of America  
United States of America  
United States of America  
United States of America  

CISTM12 Scientific Committee

Christoph Hatz  
Mary E. Wilson  
Christina Greenaway  
Leo Visser  
Elizabeth Barnett  
Buddha Basnyat  
Jiri Beran  
Frank J. Bia  
Garth Brink  
Gerd Burchard  
Francesco Castelli  
Lin Chen  
Joaquim Gascon  
Alfons van Gompel  
Sheila C.K. Hall  
Phyllis E. Kozarsky  
Karin Leder  
Peter A. Leggat  
Ziad Memish  
Maria D. Mileno  
Margot Muetsch  
Tomas Orduna  
Philippe Parola  
Nancy Piper Jenks  
Watcharapong Piyaphanee  
Edward T. Ryan  
Suzy Sarfaty  
Patricia Schlagenhauf  
Heli Siikamäki  
Rudy Zimmer  

Switzerland - Chair  
United States of America - Co-Chair  
Canada - Associate Chair  
The Netherlands - Associate Chair  
United States of America  
Nepal  
Czech Republic  
United States of America  
South Africa  
Germany  
Italy  
United States of America  
Spain  
Belgium  
United Kingdom  
United States of America  
Australia  
Australia  
Saudia Arabia  
United States of America  
Switzerland  
Argentina  
France  
United States of America  
Thailand  
United States of America  
United States of America  
Switzerland  
Finland  
Canada
Acknowledgements and Supporters

Supporters of ISTM

— Gold Supporters —

NOVARTIS VACCINES

— Additional Supporters —

Salix®
PHARMACEUTICALS, INC.
ADVANCING TREATMENT IN GASTROENTEROLOGY

SHORELAND

sigma-tau
Important Information

Identification
Participants are requested to wear their name badges while in attendance.
• Full Delegate Badge: All activities throughout the Conference
• One Day Badge: All activities on the specified day
• Accompanying Person Badge: Welcome Get Together, Exhibit Hall and Coffee Breaks
• Persons not wearing a badge will be denied admission to the conference sessions.

Liability
The 12th Conference of the International Society of Travel Medicine in no event shall be liable for acts or defaults in the event of injury, damage, loss, accident, delay or irregularity of any kind whatsoever during arrangements organized through contractors or the employees of such contractors in performing services. The organizers reserve the right to make changes, where deemed necessary, without prior notice to parties concerned.

Speaker Ready Room
The Speaker Ready room is located in the John B. Hynes Convention Center Room 307. The Speaker Ready Room hours as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 8 May 2011</td>
<td>08:00-17:00</td>
</tr>
<tr>
<td>Monday, 9 May 2011</td>
<td>07:00-17:00</td>
</tr>
<tr>
<td>Tuesday, 10 May 2011</td>
<td>07:00-17:00</td>
</tr>
<tr>
<td>Wednesday, 11 May 2011</td>
<td>07:00-16:00</td>
</tr>
<tr>
<td>Thursday, 12 May 2011</td>
<td>07:00-11:00</td>
</tr>
</tbody>
</table>

Speakers can bring files on CD-Rom or Memory Stick, as we suggest you bring at least one back-up of your presentation. Presentations are to be brought to the Speaker Ready Room 24 hours prior to your session.

Evaluation Form
You will find an evaluation form in your conference bag. Please take a few minutes to evaluate the sessions you attend. The form can be returned to the Registration Desk.

Medical Education Credits
CME Credits: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Emory University School of Medicine and the International Society of Travel Medicine. The Emory University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Emory University School of Medicine designates this continuing medical education activity for a maximum of 23 American Medical Association Physician’s Recognition Award Category 1 Credit(s)™. Each physician should only claim credit commensurate with the extent of his/her participation in the activity.

It is the intent of Emory University School of Medicine to assure that its educational mission, and Continuing Medical Education activities in particular, should not be influenced by the special interests of individuals associated with its programs. Having an interest in or an affiliation with any corporate organization does not necessarily influence a speaker’s presentation, but the relationship must be made known in advance to the audience in accordance with the Standards of the Accreditation Council for the Continuing Medical Education. All conflicts will be disclosed prior to the beginning of the program.
Welcome-Get-Together
The Welcome Get-Together will take place immediately following the Opening Ceremony on Sunday, 8 May 2011 in the Boylston Hallway located on the third level of the John B. Hynes Veterans Memorial Convention Center from 18:15 – 21:30.

Meet the History Lectures
Meet the History is a lecture series describing historical and cultural background information on Boston, Massachusetts. These sessions will take place at 08:00 on 9 May 2011 -11 May 2011.

The information listed below will direct you to locations of all on-site conference activities:

Main Entrance and Registration Area
• Pre-registration—Auditorium Pre-function 2nd Floor of the John B. Hynes Veterans Memorial Convention Center
• New Registration—Auditorium Pre-function 2nd Floor of the John B. Hynes Veterans Memorial Convention Center
• Meeting Point and Message Board
• Tour Desk

Registration hours are as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 7 May 2011</td>
<td>18:00-20:00</td>
</tr>
<tr>
<td>Sunday, 8 May 2011</td>
<td>10:00-20:00</td>
</tr>
<tr>
<td>Monday, 9 May 2011</td>
<td>07:00-17:00</td>
</tr>
<tr>
<td>Tuesday, 10 May 2011</td>
<td>08:00-17:00</td>
</tr>
<tr>
<td>Wednesday, 11 May 2011</td>
<td>08:00-17:00</td>
</tr>
<tr>
<td>Thursday, 12 May 2011</td>
<td>08:00-14:00</td>
</tr>
</tbody>
</table>

Meeting Rooms for committees and Interest Groups are located in Rooms 302, 304 and 306 of the John B. Hynes Veterans Memorial Convention Center. Some committee meetings will be held at the Sheraton Boston Hotel.

CISTM12 Meetings

Monday, 9 May 2011
18:30-19:30
Pharmacist Professional Group Membership Assembly 
Room 302
Pediatric Interest Group Membership Assembly 
Room 304
Migrant and Refugees Interest Group Membership Assembly 
Room 306

Tuesday, 10 May 2011
07:30-08:45
GeoSentinel/Euro TravNet Network Members Meeting 
Fens Room
5th Floor Sheraton Hotel Boston

18:30-19:30
Nursing Professional Group Membership Assembly 
Room 302
Psychological Health of Travelers Interest Group Membership Assembly 
Room 304
Destination Communities Support Interest Group Membership Assembly 
Room 306
Hynes Convention Center - Level 2

Hynes Convention Center - Level 3
Plenary Lectures
The 4 plenaries (PL01-PL04) during the meeting are meant to highlight areas at the forefront of travel medicine. In general these are internationally prominent invited speakers with expertise allied to travel medicine who delegates would like to hear, but who would not otherwise attend a travel medicine meeting. Each speaker is allotted 30 minutes; there is no discussion period during plenary sessions. There are no concurrent sessions running during plenaries.

Symposium Lectures
The 14 symposia (SY01-SY14) during the meeting are meant to highlight areas at the forefront of daily travel medicine practice. The topics are more focused than the plenaries and in many cases will appeal most to subsets of 4 delegates with special interests. Each speaker is allotted 25 minutes for their presentation with 5 minutes for questions. Symposia are held in rooms holding from 500-1800 persons and will run concurrently with 3 other sessions.

Workshop Sessions
Each workshop session (WS01-WS20) is designed to promote dialogue between 2 experts on a topic in the field of travel medicine and individuals in practice who have experiences to share and questions to ask. While designed to be intimate and interactive, experience indicates that workshop audiences will vary from 40-400 people. Practical information that will give participants insight into the most current strategies for prevention, self-treatment, and diagnosis should be emphasized. Workshop chairs will have developed a set of 4-6 non-overlapping clinical scenarios or case histories designed to stimulate discussion/learning between themselves and the workshop participants. These should encompass the most common clinical situations within topics that present in everyday practice. Workshops are not intended to be modified lectures and the use of formal slides or presentation material will be kept to a minimum. All workshop sessions are concurrent with 4 other sessions.

ABC Workshop Sessions
Each ABC workshop session is designed to promote dialogue between 2 experts on a topic in the field of travel medicine and individuals new to the practice of travel medicine who have many questions. As for regular workshops the format will consist of a set of 4-6 non-overlapping clinical scenarios or case histories designed to stimulate discussion/learning. The emphasis is on practical information that will give insight into the most current strategies for prevention, self-treatment, and diagnosis. ABC workshops are designed to educate the relative novice to travel medicine; scenarios and questions are designed with this in mind. In most cases similar topics will also be covered in one or more standard workshop sessions so leaders will be diligent in keeping the discussion oriented to those new to travel medicine.

Destination Workshops
Workshop chairs will have developed a set of 4-6 non-overlapping clinical scenarios or case histories designed to stimulate discussion/learning between themselves and the workshop participants. These encompass the most common clinical situations facing travelers to that specific country that present in everyday practice. Workshops are not intended to be modified lectures and the use of formal slides or presentation material will be kept to a minimum. However, the extensive use of photographic slides depicting geography, topography, climate, and ambient conditions at the destination in order to illustrate risk for travel-related morbidity will be emphasized.

Debate
The debate during the meeting is meant to highlight a controversial area at the forefront of travel medicine. This format will feature 2 highly experienced ISTM members. Five specific issues under the broad topic will be debated. Each debater will get 2 minutes for opening remarks. Then for each issue, debaters will give a 5 minute prepared presentation (slides allowed) and the one that spoke first will be given 2 minutes for rebuttal. Twenty minutes of the 90-minute block will be available for questions from the audience to the debaters.
Guide to Session Formats

Free Communications Oral Sessions
Each session (FC01-FC08) will consist of presentations of the latest original research, case studies, or experiences of travel medicine peers. Each presentation will be 10-minutes in length with 5 minutes for questions and discussion. These sessions are concurrent with 4 other sessions.

Posters
Posters are presented (PO.01-PO.16.07) on the latest original research, case studies or experiences of travel medicine peers. Posters will be available for viewing from Monday, 9 May 2011 at 10:30 until Wednesday, 11 May 2011 in the Exhibit Hall. Authors will be in attendance on Wednesday, 11 May 2011 from 16:15 to 17:15.

Case of the Day
In a 30-minute early morning session (COD1-COD4), an expert in travel medicine will present a case from his practice that is both interesting and informative to attending delegates. The cases will raise issues of diagnosis and therapy that will stimulate discussion and participation by those attending.

Meet the Professor
In a 30-minute early morning session (MTP1-MTP4) travel medicine experts will meet with attendees who will be able to seek opinions on topics and issues of their own choosing.
Faculty Disclosure

Jesse Alves
Susan Anderson
Oscar Arocha
Karen Avery
Howard Backer
Kevin Baird
Maura Baker
Elizabeth Barnett
Budha Basnyat
Ron Behrens
Miriam Navarro Beltrá
Jiri Beran
Frank Bia
Ralf Bialek
Johannes Blum
Suni Boraston
Garth Brink
John Brownstein
Adrian Hopperus Buma
Gerd Dieter Burchard
David Burger
Phillippe Calain
Francesco Castelli
Eric Caumes
Marty Cetron
Santanu Chatterjee
Lin Chen
Bradley Connor
Fiann Crane
Kenneth Dardick
Alfred DeMaria
JC Pinto Dias
Herbert DuPont
Charlie Ericsson
Doug Esposito
David Freedman
Joaquim Gascon
Phillippe Gautret
Fiona Genasi
Blaise Genton
Jeff Goad
Larry Goodyer
Sherwood Gorbach
Christina Greenaway
Sheila Hall
David Hamer
Steve Hargarten
Christoph Hatz
Howard Heller
Patrick Hickey
David Hill
Charles Hoge
Christine Hunter
Yves Jackson
Tomas Jelinek
Nancy Piper Jenks
Emily Jentes
Kirsten Johnson
Jay Keystone
CN Kotton
Phyllis Kozarsky
Ted Lankester
Regina La Rocque
Karin Leder
Peter Leggat
Michael Libman
Daniel Libraty
Poh Lian Lim
Joann Liu
Thomas Löscher
Louis Loutan
Sue MacDonald
Sheila Mackell
Alan Magill
J Maguire
Alberto Mattei
Anne McCarthy
Susan Mclellan
Ziad Memish
Marc Mendelson
Maria Mileno
Jeffrey Miller
Deborah Mills
Tom Monath
Margot Muetsch
Hans Nothdurft
Tomas Orduna
Robert Orenstein
Prativa Pandey
Phillipe Parola
Cecilia Perret
Watcharapong Piyanpanee
Mathieu Potin
Gilles Poumerol
Meb Rashid
Cate Riley
Gail Rosselot
Michel Roulet
Cecile Rousseau
Edward T. Ryan
Michele Sabourin
Patricia Schlagenhauf
Eli Schwartz
Mary Louise Scully
Evelyn Sharpe
Marc Shaw
Heli Siikamäki
David Shlim
Annelies Wilder Smith
William Stauffer
Robert Steffen
Bernard Stockman
Dominique Tessier
Joseph Torresi
Erik van Vliet
Leo Visser
Alfons van Gompel
Frank von Sonnenburg
Betsy Wade
Steve Whitehead
Mary Wilson
Claire Wong
Caroline Zeind
Rudolph Zimmer
Thomas Zoller
Nick Zwar

The footnoted Speakers have indicated that they have relationships with the entries listed below which, in the context of their presentation(s), could be perceived as a potential conflict of interest (e.g., direct research funding from a commercial organization, etc.)

1. Merck – research support, consultant; Bristol-Myers Squibb, Roche, Abbot – research support
2. Novartis, Sanofi Aventis – honorarium
3. Shoreland – consulting fees; Novartis Vaccines – travel
4. Nomad Medical, salary and expenses; GSK, Sigma-Tau, Norgine – consultant fee
5. Novartis Vaccine - honorarium
6. Sanofi Pasteur, Intercell, Novartis, Crucell, GSK – honorarium
7. Sigma-Tau – honorarium
8. GlaxoSmithKline, Pfizer – honorarium
Opening Ceremony Sunday, 8 May 2011

– Opening Ceremony –

Chairs: Alan J. Magill, ISTM President, United States of America
       Davidson Hamer, CISTM12 LOC Chair, United States of America

17:00-18:15
BALLROOM A-C
John B. Hynes Memorial Convention Center

17:00
Introduction of the Longwood Symphony Orchestra
Davidson Hamer, CISTM12 LOC Chair, United States of America

17:00-17:15
Around the World with the Longwood Symphony Orchestra
Lawrence Isaacson, Guest Conductor

   From Norway, Edvard Greig’s “Holberg Suite, Prelude”
   From Austria, Franz Shreker’s “Intermezzo”

17:15-17:20
Welcome to the CISTM12
Alan J. Magill, ISTM President, United States of America

17:20-17:25
Welcome to Boston
Davidson Hamer, CISTM12 LOC Chair, United States of America

17:25-17:30
Local Political Dignitary
TBD

17:30-17:35
The Scientific Program of the CISTM12
Christoph Hatz, CISTM12 Scientific Committee Chair, Switzerland

17:35-17:55
Keynote Speaker, “Travel Medicine: 20 Years and Beyond”
Robert Steffen, Switzerland

17:55-18:05
Award and Remarks
Alan J. Magill, ISTM President, United States of America

18:05-18:10
Close
Davidson Hamer, CISTM12 LOC Chair, United States of America

18:10-18:15
Thanks and introduction of Longwood Symphony Orchestra
Alan J. Magill, ISTM President, United States of America

   From England, Gustav Holst’s “St. Paul Suite, Ostinato”
   From Germany, Wolfgang Amadeus Mozart’s “Divertimento, K. 136 in D major, Presto”

– Welcome Get Together –

Chairs: Alan J. Magill, ISTM President, United States of America
       Davidson Hamer, CISTM12 LOC Chair, United States of America

18:15-21:30
BOYLSTON HALLWAY
John B. Hynes Veterans Memorial Convention Center.
### CISTM12 Program Saturday, 7 May 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00-20:00</td>
<td>Congress Registration</td>
<td>Auditorium Pre-function</td>
</tr>
</tbody>
</table>

### CISTM12 Program Sunday, 8 May, 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:30-08:00</td>
<td>Registration for the CTH® Exam</td>
<td>Exhibit Hall D Pre-function</td>
</tr>
<tr>
<td>08:00-12:45</td>
<td>CTH® Exam</td>
<td>Hall D</td>
</tr>
<tr>
<td>10:00-20:00</td>
<td>Congress Registration</td>
<td>Auditorium Pre-function</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Pre-CISTM Course 1, Cross-Cultural Travelers: Pre-travel Psychological Screening, and Post Travel Psychological Care</td>
<td>Room 303</td>
</tr>
</tbody>
</table>

**The Resilience Audit – Purpose and Practice**

*Annie Hargrave, United Kingdom*

- How and why we have built this clinical service
- Positives and pitfalls
- Purpose in focus
- Practice in focus – with feedback from pilot programme

**A Psychological Profile of 200 Aid Workers and Missionaries Prior to Overseas Posting**

*Ken Gamble, Canada*

- Significant findings
- Link to health problems in the field and on return
- Benefit and pitfalls

**Management of Psychological Problems During and After Return of Field Missions**

*Sigiriya Aebischer Perone, Switzerland*

- Background of the International Committee of the Red Cross work
- Presentation of 3-4 case studies
- Analysis of the different stressors and precipitant factors
- Intervention strategies on-site and after return
- Specialists referral and follow-up until recovery
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-16:30</td>
<td>Care of Families on Return from Overseas</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mike Jones, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Setting the scene</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Third culture kids and international nomads</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Similarities and differences of response on return to country of origin</td>
<td></td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Pre-CISTM Course 2</td>
<td>Room 301</td>
</tr>
<tr>
<td></td>
<td>Migrant Medicine: Practical and Clinical Aspects of Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Cases Highlighting Key Screening Concepts and Management Approaches</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jose Debes, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>David Boulware, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anne McCarthy, Canada</td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>Transforming Data about Migrants to Migrant Health Solutions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>William Stauffer, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tarissa Mitchell, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Miriam Navarro Beltrá, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rogelio López-Vélez, Spain</td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>Addressing Health Disparities in Migrant Populations - Beyond Access to Health Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr. Patricia F. Walker, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>At the end of this session participants will, through case-based examples:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the risks related to strongyloides for new and distant migrants.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the clinical presentations of stronglyloides.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recognize RED FLAG conditions that may predispose migrants for severe strongyloidiasis.</td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>Nurses’ Reception</td>
<td>Constitution A at the Sheraton Boston Hotel</td>
</tr>
<tr>
<td>17:00-18:15</td>
<td>Opening Ceremony</td>
<td>Ballroom A-C</td>
</tr>
<tr>
<td></td>
<td>John B. Hynes Veterans Memorial Convention Center</td>
<td></td>
</tr>
<tr>
<td>18:15-21:30</td>
<td>Welcome-Get-Together</td>
<td>Boylston Hallway - 3rd Floor</td>
</tr>
<tr>
<td></td>
<td>John B. Hynes Veterans Memorial Convention Center</td>
<td></td>
</tr>
</tbody>
</table>
## CISTM12 Program Monday May, 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-17:00</td>
<td>Congress Registration</td>
<td>Auditorium Pre-function</td>
</tr>
<tr>
<td>MTH1</td>
<td>Meet the History 1</td>
<td>Room 302</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>Smallpox in Massachusetts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alfred DeMaria, United States of America</td>
<td></td>
</tr>
<tr>
<td>MTP1</td>
<td>Meet the Professor 1</td>
<td>Room 304</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>Bradley Connor, United States of America</td>
<td></td>
</tr>
<tr>
<td>COD1</td>
<td>Case of the Day 1</td>
<td>Room 306</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>Sheila Hall, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>PL01</td>
<td>Plenary</td>
<td>Ballroom A-C</td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>Disaster Response: Haiti</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Christoph Hatz, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alan Magill, United States of America</td>
<td></td>
</tr>
<tr>
<td>PL01.01</td>
<td>Lessons Learned from the 2010-2011 Experience</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joanne Liu, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Understand the successes and shortcomings of a deployment of a massive presence of relief organisations in an exceptional natural disaster situation over one year.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Learn the conclusions drawn from a practical experience for future deployments.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Understand the proposed changes and/or confirmations drawn from the experience.</td>
<td></td>
</tr>
<tr>
<td>PL01.02</td>
<td>Military Response and Collaborations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Christine Hunter, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appreciate the preparations for a disaster relief deployment.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Understand the main logistical challenges of the military working in a disaster situation in Haiti</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appreciate the challenges and successes of the US military forces with regard to collaboration with others, including coordination issues.</td>
<td></td>
</tr>
<tr>
<td>PL01.03</td>
<td>Clinical Experience</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michel Roulet, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Understand the management of project cycle in complex humanitarian emergencies (rapid initial assessment, strategy, implementation, crisis cell, local capacity building)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appreciate the medical challenges, including triage under logistic and personnel constraints</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interpret humanitarian medicine as evidence-based medicine</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>10:30-11:15</td>
<td>Opening of Commercial Exhibits/Break</td>
<td>Auditorium</td>
</tr>
<tr>
<td></td>
<td><strong>SY01</strong> Symposium</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td><strong>Risks and Costs in Travel Medicine</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Karl Neumann, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lars Rombo, Sweden</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY01.01 Vaccine Skepticism</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Margot Muetsch, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recalls the background of vaccine skepticism in special populations.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Lists ways on how to overcome vaccine skepticism.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recognizes the need of sound scientific evidence on the benefit of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>vaccines vs gut feelings taken seriously.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**SY01.02 The Prevention of Low Risk — High Consequence Diseases in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Travel Medicine**</td>
<td></td>
</tr>
<tr>
<td></td>
<td>David Shlim, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Explain that very rare diseases may not have an agreed upon</td>
<td></td>
</tr>
<tr>
<td></td>
<td>threshold for immunization among different Travel Practitioners.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Explain the risk of rare diseases in terms of likelihood and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>consequences.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recognize the costs involved in preventing rare diseases in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>travelers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**SY01.02 Rabies Pre-Travel Vaccination: Who Needs it? Who Can Afford</td>
<td></td>
</tr>
<tr>
<td></td>
<td>It?**</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Philippe Gautret, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the available pre-travel vaccination schedules.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Collect evidence- and expert-based information for the assessment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>of the benefit of rabies vaccination</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss the possible cost-saving measures in pre-travel rabies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>vaccination, including their short-comings</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY02</strong> Symposium</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td><strong>Through the Eyes of a Migrant</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Irmgard Bauer, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Overbosch, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>SY02.01 <strong>Ecuadorian</strong>&lt;br&gt;Nancy Piper Jenks, United States of America</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Understand some of the basic health issues and epidemiology of disease of a large Ecuadorian population who have migrated through Central America to arrive in New York.&lt;br&gt;• Appreciate the stresses and dreams associated with migration through a number of personal stories of Ecuadorians from Azuay.&lt;br&gt;• List some of the health care needs of this population and how these needs can be addressed through an innovative model of care.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SY02.02 <strong>Bolivian</strong>&lt;br&gt;Yves Jackson, Switzerland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Understand the patterns and characteristics of bolivian emigration to Europe and Switzerland in particular.&lt;br&gt;• Understand bolivian immigrants life experiences in Geneva.&lt;br&gt;• Be aware of major health problems - with a focus on Chagas disease - and challenges in access to care.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SY02.03 <strong>Southeast Asian</strong>&lt;br&gt;Meb Rashid, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Understand the refugee migration to Canada highlighting the unique aspects of the Karen migration.&lt;br&gt;• Appreciate the approach that is implemented to address the unique needs of this particular group.&lt;br&gt;• Learn about the medical and social needs that challenge the Karen community in Canada.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS01 <strong>Workshop</strong>&lt;br&gt;Yellow Fever (ABC)&lt;br&gt;David Hill, United Kingdom&lt;br&gt;Gilles Poumerol, Switzerland</td>
<td>Ballroom C</td>
<td></td>
</tr>
<tr>
<td>• Describe the key aspects of yellow fever disease and epidemiology&lt;br&gt;• Be able to apply the principles of risk assessment for yellow fever vaccination to their travellers through participation in case studies&lt;br&gt;• Be able to assess the risk of adverse events following yellow fever vaccination in their travellers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>WS02</td>
<td>Workshop&lt;br&gt;<strong>Emergencies in Travel Medicine</strong>&lt;br&gt;<strong>Susan Anderson,</strong> United States of America&lt;br&gt;<strong>Mathieu Potin,</strong> Switzerland</td>
<td>Room 302</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td>• List the major and most frequent emergency related situations that can occur to travelers&lt;br&gt;• Are able to guide and council several specific types of travelers in relation to their specific risk either activities related or either co-morbidities related&lt;br&gt;• Design advice to cope with travel emergencies related issues: travel health kit (for the traveler, for the doctor), insurance coverage and access to care while abroad</td>
<td></td>
</tr>
<tr>
<td>FC01</td>
<td>Free Communication&lt;br&gt;<strong>Malaria and Other Parasitic Infections</strong>&lt;br&gt;Chairs: <strong>Sonny Lau,</strong> Australia&lt;br&gt;<strong>Thomas Loescher,</strong> Germany</td>
<td>Room 306</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td>FC01.01 <em>Does Community Subsidised Malaria Chemoprophylaxis Reduce Imported Malaria? A Case Control Study of Policy</em>&lt;br&gt;Neave P., Allwood D., Behrens R.H.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FC01.02 <em>Nitroimidazole Resistant Giardia Intestinalis in Travellers: Is it More Frequent Than Expected?</em>&lt;br&gt;Muñoz J., Aldasoro E., Comin A.M., Valls M.E., Del Cacho E., Pinazo M.J., Bardaji A., Oliveira I., Mas J., Gascon J.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FC01.03 <em>Prolonged Prophylactic Efficacy of Atovaquone/Proguanil to Prevent Malaria</em>&lt;br&gt;Deye G.A., Miller R.S., Miller L., Salas C., Tosh D., DiTusa C., Macareo L., Smith B., Magill A.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FC01.04 <em>Use of Malaria Imported Cases in Non Endemic Countries to Assess the Return of Chloroquine Susceptibility of P. Falciparum Strains From Senegal</em>&lt;br&gt;Gharbi M., Pradines B., Kendjo E., Hubert V., Guerin P.J., Le Bras J.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FC01.05 <em>Do They Really Sleep? Sleeping Sickness in Travelers</em>&lt;br&gt;Blum J.A., Urech K.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FC01.06 <em>Analysis of 160 Cases of LOA</em>&lt;br&gt;Puente S., Subirats M., Rivas P., Lago M.M., Herrero M.D., Ramírez-Olivencia G.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>SY03</td>
<td>Symposium&lt;br&gt;<strong>Yellow Fever Risk: Location and Movement</strong>&lt;br&gt;Chairs: <strong>Marty Cetron,</strong> United States of America&lt;br&gt;<strong>David Hill,</strong> United Kingdom</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>14:45-16:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td></td>
<td><strong>SY03.01 Yellow Fever: The Changing Landscape of Epidemiology and Vaccination</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tom Monath, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the scientific basis for yellow fever maps.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Appreciate the factors associated with changes in the distribution of yellow fever risk.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Know new approaches to yellow fever vaccine development.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY03.02 Updates of Revisions of Yellow Fever Risk Mapping and Vaccine Recommendations 2010-2011: A CDC Perspective</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emily Jentes, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Be able to communicate the methods of redefining the YF risk areas.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Be able to communicate and act on the changes in the CDC vaccine recommendations.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Be able to access the maps and recommendations.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Other Perspectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gilles Poumerol, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peter Leggat, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Panel Discussion and Q&amp;A: All speakers</strong></td>
<td></td>
</tr>
<tr>
<td>SY04</td>
<td><strong>Symposium</strong></td>
<td>Ballroom A</td>
</tr>
<tr>
<td>14:45-16:15</td>
<td><strong>Water-Related Hazards</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Martin Grobusch, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Elaine Jong, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY04.01 Water Related Bacterial and Parasitic Infections</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eli Schwartz, Israel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the most important water related bacterial and parasitic infections (except for schistosomiasis) and state the three most important ones.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Assess the diagnostic steps for the respective diseases.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Manage water related bacterial and parasitic infections - appropriate medication selection, review pharmacokinetics/side effects</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY04.02 Misconceptions in Schistosomiasis Management</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marc Mendelson, South Africa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the diagnostic measures necessary at each stage of schistosomiasis infection (invasive, prepatent, Katayama fever, egg-shedding stages).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the preventive measures against infection.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe management of schistosomiasis at each of the different stages.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Assess post-treatment outcome and manage accordingly.</td>
<td></td>
</tr>
</tbody>
</table>
SY04.03 Marine and Aquatic Injuries
Bernard Stockman, Belgium
- List the clinically most important marine and aquatic injuries (except for schistosomiasis, leptospirosis and other hazards covered by the other two speakers).
- Identify emergency and follow-up management of marine and aquatic injuries.
- Communicate preventive measures to travelers at potential risk.

WS03 Workshop
Networks and Mapping
14:45-16:15
Ballroom C
John Brownstein, United States of America
Philippe Parola, France
- Recognize the use of travel clinic report as an early warning system.
- Recognize the use of web-based data as epidemic intelligence.
- Recognize the use of travel clinic network to prevent the introduction of infectious diseases into Europe.

WS04 Workshop
The Traveler with Chronic Disease
14:45-16:15
Room 302
Anne McCarthy, Canada
Susan McLellan, United States of America
- Identify the key messages of pre-travel advice, including the value of vaccinations and chemoprophylaxis for travelers with chronic diseases
- Be able to communicate preventive measures to travelers with chronic diseases.
- Describe, using illustrative examples, travel medicine preparation in special hosts, particularly those with HIV, ESRD, DM, and post-transplant.
- Recall some additional resources for these travelers/their travel medicine providers.

FC02 Free Communications
Travel Advice
14:45-15:00
Room 306
Chairs: Jeffrey Goad, United States of America
Herwig Kollaritsch, Austria
FC02.01 Demographics, Travel Destinations and Pre-Travel Health Care Among U.S. International Travelers: Analysis of the Global TravEpiNet Surveillance Network
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
</table>
| 15:00-15:15| **FC02.02** *Introducing the PRE-TRAVEL Model*  
Willcox A., Adams A.E., Dale J. |            |
| 15:15-15:30| **FC02.03** *Provider Decision-Making Regarding Yellow Fever Vaccine Administration*  
| 15:30-15:45| **FC02.04** *The Reliability of Pre-Travel History to Decide on Appropriate Counseling and Vaccinations: A Prospective Study*  
Rossi I.A., Genton B. |            |
| 15:45-16:00| **FC02.05** *“Thanks Doctor! “ “Actually, I’m a Nurse!” - An Evaluation of the Satisfaction of Clients According to the Type of Health Professional Seen*  
Rochat J., Genton B., Rossi L., Uwanyiligira M., Cathieni F., de Valliere S. |            |
| 16:00-16:15| **FC02.06** *Immediate Recall of Health Issues Discussed During a Pre-Travel Consultation*  
| 16:15-17:00| Break/Exhibition | Auditorium |
| SY05       | **Symposium**  
**State of the Art Treatment of Imported Parasitic Diseases**  
Chairs: Frank Bia, United States of America  
Alfons von Gompel, Belgium | Ballroom B |
| 17:00-18:30| **SY05.01** *Common Intestinal Protozoa: What Are the Options?*  
Davidson Hamer, United States of America |

- Identify the epidemiology, risk factors for and clinical presentation of common intestinal protozoa with a focus on Giardia lamblia and Entameoba histolytica.
- List the efficacy of different pharmaceutical treatment options for Giardia lamblia, discuss how to prescribe and manage patient and those with relapses.
- Discuss pharmaceutical management options for less commonly encountered protozoa including Cryptosporidium, Cyclospora, and Blastocystis hominis.
- Identify the pharmaceutical management issues and treatment options for Entameoba histolytica hepatic abscesses and colitis.
**SY05.02 Malaria: How to Treat Severe Malaria in Industrialized Countries**
*Thomas Zoller*, Germany

- Understand the groups at risk for severe malaria in industrialized countries and their clinical presentation.
- Learn about the different anti-malarial therapies available to treat severe malaria.
- Learn about the role of adjunctive therapies in managing severe malaria such as exchange transfusion, systemic antibiotics etc.

**SY05.03 How to Cope with the Wormy World: Treatment of Helminths**
*Michael Libman*, Canada

- Understand the epidemiology, risk factors for and clinical presentation of selected important geohelminths: strongyloides, hookworm and ascaris.
- Be aware of the different diagnostic tests available for these organisms and their limitations.
- Learn about the different treatment options for these organisms.

**SY05.04 Leishmaniasis: Species Specific Treatment Guided by Molecular Diagnostics**
*Johannes Blum*, Switzerland

- Define the criteria of a complex lesion of cutaneous leishmaniasis to determine the most appropriate (for decision making for) topical and/or systemic pharmaceutical treatment options.
- Assess the risk of developing a mucosal lesion.
- List the most relevant pharmecutical treatment options for species specific (oriented treatment of) cutaneous.

**SYM06 Symposium**
*Psychological Health Issues in Long Term Travelers*
Chairs: *Gary Brunette*, United States of America
*Ted Lankester*, United Kingdom

**SY06.01 Humanitarian Aid Workers and Missionaries: How Can We Increase Psychological Resilience?**
*Evelyn Sharpe*, United Kingdom

- Knows which psychological health problems occur most frequently in HAW.
- Knows which risk factors are associated with psychological health problems in HAW.
- Can recognize signs and symptoms of psychological health problems in HAW.
- Knows which interventions are effective in increasing psychological resilience.
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>SY06.02 - Migrants and Refugees: How Can Mental Health Problems be Identified and Addressed?</strong>&lt;br&gt;Cecile Rousseau, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Knows which psychological health problems occur most frequently in migrants and refugees.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Can identify risk factors that are associated with psychological health problems.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Knows how to recognize signs and symptoms psychological health problems. Knows which interventions are effective in addressing these psychological problems.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY06.03 The Military: Evaluation and Treatment of War Trauma: What Have We Learned from U.S. Military Operations in Iraq and Afghanistan?</strong>&lt;br&gt;Charles Hoge, United States of America</td>
<td></td>
</tr>
<tr>
<td>WS05</td>
<td><strong>Workshop</strong>&lt;br&gt;Case Studies: Adventure Travel and High Altitude&lt;br&gt;Howard Backer, United States of America&lt;br&gt;Prativa Pandey, Nepal</td>
<td>Ballroom C</td>
</tr>
<tr>
<td>17:00-18:30</td>
<td>• Participants will learn to advise and prepare travelers with common medical conditions going to high altitude destinations.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List preventive and treatment strategies of high altitude illness.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Participants will learn to integrate an approach to medical screening to match travelers with appropriate adventure travel trips, considering level of fitness and other medical limitations.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify whom will be able to communicate and advise travelers about animal bites. Recommend rabies pre-immunization and what to do should a bite occur during travel.</td>
<td></td>
</tr>
<tr>
<td>WS06</td>
<td><strong>Workshop</strong>&lt;br&gt;Routes of Vaccination&lt;br&gt;Mary Louise Scully, United States of America&lt;br&gt;Leo Visser, The Netherlands</td>
<td>Room 302</td>
</tr>
<tr>
<td>17:00-18:30</td>
<td>• List the unique characteristics of the different routes of vaccination.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe how to vaccinate SQ, IM, and intradermaly.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss the future of developments in vaccines by the oral route, such as oral cholera vaccines.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
</tbody>
</table>
| FC03 17:00-18:30 | Free Communications  
Risk Factors and Travel  
Chairs: Sue MacDonald, Canada  
Pieter van Theil, The Netherlands | Room 306   |
| 17:00-17:15 | FC03.01 Acute Mountain Sickness among Travelers to Cusco-Peru (3,310 m)  
Swanson J., Salazar H., Mozo K., White Jr. A.C., Cabada M.M. |            |
| 17:15-17:30 | FC03.02 5 Years Experience of Aeromedical Evacuation of 4’882 Travelers back to Switzerland: Implications for Pretravel Counseling?  
Potin M., Seiler O. |            |
| 17:30-17:45 | FC03.03 Factors of Health and Well-being Associated with International Work-related Travel  
Bergbom B., Louekari M., Vesala H. |            |
| 17:45-18:00 | FC03.04 Travel Medicine in the Face of a Crisis  
Boddington N.L., Field V., Davies C., Lankester T. |            |
| 18:00-18:15 | FC03.05 Risk Perception of Travelers to Tropical and Subtropical Countries  
Zimmermann R., Zumbrunn S., Hattendorf J., Nüesch R., Hatz C. |            |
| 18:15-18:30 | FC03.06 Innovative Community-based Initiatives to Engage VFR Travelers  
Leder K., Hudson B., Lau S., Leggat P. |            |
| 18:30-19:15 | Special Update  
Highlights from the New Editions  
Giles Poumerol, WHO  
Gary Brunette, CDC  
David Hill, NaTHNaC | Ballroom B |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-17:00</td>
<td>Congress Registration</td>
<td>Auditorium Pre-function</td>
</tr>
<tr>
<td>MTH2</td>
<td>Meet the History</td>
<td>Room 302</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>Past, Present and Future of Travelers’ Diarrhea</td>
<td>Room 302</td>
</tr>
<tr>
<td></td>
<td>Sherwood Gorbach, United States of America</td>
<td></td>
</tr>
<tr>
<td>MTP2</td>
<td>Meet the Professor 2</td>
<td>Room 304</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>Herbert DuPont, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phyllis Kozarsky, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert Steffen, Switzerland</td>
<td></td>
</tr>
<tr>
<td>COD2</td>
<td>Case of the Day 2</td>
<td>Room 306</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>Kenneth Dardick, United States of America</td>
<td></td>
</tr>
<tr>
<td>PL02</td>
<td>Plenary</td>
<td>Ballroom A-C</td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>Dengue: Into the Future</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Fiona Genasi, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mary Wilson, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PL02.01 Quo Vadis?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Annelies Wilder-Smith, Singapore</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the changing epidemiology of dengue infections globally.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• State the reasons for the changing transmission patterns.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the epidemiology of dengue in travelers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PL02.02 Antibody Dependent Enhancement Theory for DHF: True or Not True?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daniel Libraty, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the immune response to dengue infection.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recognize the complexity of the immune response given multiple dengue serotypes.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List hypotheses that have been proposed to explain severe and complicated dengue, including antibody-dependent enhancement. Please have a careful look at the suggested objectives and edit or revise them as needed. Please send us a response by February 28th. If we do not receive an edited version by that date, we will assume that you approve the objectives stated above.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PL02.03 Dengue Vaccines: To Be or Not to Be?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steve Whitehead, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the obstacles to the development of an effective dengue Vaccine.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recognize the range of approaches that are being tried.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Summarize the current status of dengue vaccine development.</td>
<td></td>
</tr>
<tr>
<td>10:30-11:15</td>
<td>Break/Exhibition</td>
<td>Auditorum</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>SY07</td>
<td><strong>Symposium</strong></td>
<td>Ballroom B</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td><strong>Travel Advice: Are We Barking Up the Wrong Tree?</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: <strong>Rebecca Acosta</strong>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Eli Schwartz</strong>, Israel</td>
<td></td>
</tr>
<tr>
<td>SY07.01</td>
<td><strong>Road Death Toll in Tourist Destinations</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Steve Hargarten</strong>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the epidemiology of road deaths and injuries among travelers abroad.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the different risks among travelers in different parts of the world for road deaths and injuries.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recall the science of injury prevention and control and its specific application to travel medicine.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss pre-travel advice and policy for business and pleasure travelers.</td>
<td></td>
</tr>
<tr>
<td>SY07.02</td>
<td><strong>Mental Health and the Global Traveler</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Ted Lankester</strong>, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the nature and extent of mental health problems in travelers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Compare and contrast ways in which significant mental health problems can be assessed before longer term travel so support can be provided.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify appropriate ways of offering care and counselling on return from travel abroad.</td>
<td></td>
</tr>
<tr>
<td>SY07.03</td>
<td><strong>Sex, Drugs and Tattoos</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Jay Keystone</strong>, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify (appreciate the amount of) health problems related to sex, drugs and other risks transmitted with body fluids.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List (know) the different risks for drug addicts overseas.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss (learn) in a practical and catchy way (to convey) the key messages to prevent (prevention of) sexually transmitted diseases in travelers.</td>
<td></td>
</tr>
<tr>
<td>SY08</td>
<td><strong>Symposium</strong></td>
<td>Ballroom A</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td><strong>Chagas: Blood, Bugs and Oral Transmission</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: <strong>Rogelio López-Vélez</strong>, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Tomas Orduna</strong>, Argentina</td>
<td></td>
</tr>
<tr>
<td>SY08.01</td>
<td><strong>Epidemiology of Chagas in the Immigrant Population Outside of the US</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Miriam Navarro Beltrá</strong>, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Know the epidemiology of <em>T. cruzi</em> infection in the immigrant population outside of the Americas.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the changes in the epidemiology in migrants.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Know the types of screening programs in Europe, including those for pregnant women.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>SY08.02</td>
<td>Changing Epidemiology in Latin America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>JC Pinto Dias, Brazil</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Understand the current epidemiology of Chagas in Latin America.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Understand the reasons for the changing epidemiology of Chagas in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Latin America.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Know the factors associated with oral transmission and outbreaks in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Latin America.</td>
<td></td>
</tr>
<tr>
<td>SY08.03</td>
<td>Epidemiology in the US and Diagnosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jamie Maguire, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Know the current epidemiology of Chagas in the US.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Appreciate the types of diagnostic tests that are available and their</td>
<td></td>
</tr>
<tr>
<td></td>
<td>deficiencies.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Know the types of clinical presentations of Chagas in immigrant</td>
<td></td>
</tr>
<tr>
<td></td>
<td>populations.</td>
<td></td>
</tr>
<tr>
<td>WS07</td>
<td>Workshop</td>
<td>Ballroom C</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td>Malaria Prevention (ABC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Suni Boraston, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tomas Jelinek, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- List the key messages of malaria prevention.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Describe the value of chemoprophylaxis and stand-by treatment.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- List measures which can be taken to avoid mosquito bites.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Are able to communicate malaria preventive measures, also in view of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>behaviour during travel.</td>
<td></td>
</tr>
<tr>
<td>WS08</td>
<td>Workshop</td>
<td>Room 302</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td>South Africa (Destination)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marc Mendelson, South Africa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Erik van Vliet, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Perform an appropriate risk assessment and how to and identify health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>risks related to travel to South Africa.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- List the big 5 Health risks related to travel to South Africa.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Are able to communicate preventative measures and identify requirements</td>
<td></td>
</tr>
<tr>
<td></td>
<td>for special destinations in South Africa e.g visits to game reserves.</td>
<td></td>
</tr>
<tr>
<td>FC04</td>
<td>Free Communications</td>
<td>Room 306</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td>Potpourri</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Garth Brink, South Africa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heli Siikamaki, Finland</td>
<td></td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>FC04.01 Incidence of Influenza and Respiratory Viruses in Australian</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Travellers Visiting South and South East Asia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ratnam I., Black J., Leder K., Matchett E., Pollissard L., Luxemburger</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C., Demont C., Padaglione A., Woolley I., Panagiotidis T., Layden J.,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gherardin T., Torresi J.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td><strong>FC04.02</strong> <em>Factors Influencing the Prescription of Malarial Chemoprophylaxis and Diarrhea Self-treatment: Findings from the Boston Area Travel Medicine Network (BATMN)</em>&lt;br&gt;Hamer D.H., Hochberg N.S., Pfaff M., Chen L.H., Karchmer A.W., Wilson M.E., Benoit C.M., Yanni E., Ooi W.W., Kogelman L., MacLeod W.B., Barnett E.D.</td>
<td></td>
</tr>
<tr>
<td>11:45-12:00</td>
<td><strong>FC04.03</strong> <em>The Degree to Which Travelers are Inconvenienced by Travelers’ Diarrhea: A Prospective Follow-up Study</em>&lt;br&gt;Soonawala D., Vlot J.A., Visser L.G.</td>
<td></td>
</tr>
<tr>
<td>12:00-12:15</td>
<td><strong>FC04.04</strong> <em>Maternal and Paternal use of Mefloquine Chemoprophylaxis Prior to and During Pregnancy</em>&lt;br&gt;Schlagenhauf P., Suarez Boutros M., Suter P., Regep L., Rhein H.G., Scharer M.T., Adamcova M.</td>
<td></td>
</tr>
<tr>
<td>12:15-12:30</td>
<td><strong>FC04.05</strong> <em>Calls to a National Travel Health Advice line - Information From the National Travel Health Network and Centre (NaTHNaC)</em>&lt;br&gt;Wong C.S., Ford L., Boddington N., Launders N., Corrigan T., Simons H., Gawthrop M., Stillwell A., Jermacane D., Hill D.R.</td>
<td></td>
</tr>
<tr>
<td>12:30-12:45</td>
<td><strong>FC04.06</strong> <em>An Open Label Study of Tadalafil and Acetazolamide Versus Acetazolamide for Prevention of Severe Mountain Sickness</em>&lt;br&gt;Leshem E., Caine Y., Rosenberg E., Maaravi Y., Hermesh H., Schwartz E.</td>
<td></td>
</tr>
<tr>
<td>12:45-13:45</td>
<td>Lunch/Break</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>13:45-14:45</td>
<td><strong>Late Breaking Plenary</strong>&lt;br&gt;&lt;br&gt;Ionizing Radiation: How to Advise Patients Travelling to Japan&lt;br&gt;Scott Phillips, United States of America&lt;br&gt;Chairs: Christoph Hatz, Switzerland&lt;br&gt;David Freedman, United States of America&lt;br&gt;&lt;br&gt;<em>Understand the pathway of radioactive iodine in the environment.</em>&lt;br&gt;<em>Understand what a contaminated versus a radioactive patient means.</em>&lt;br&gt;<em>Advise their travelers as to how to take prudent precautions.</em></td>
<td></td>
</tr>
</tbody>
</table>
Travel medicine professionals have found it useful to define a subset of travelers as “visiting friends and relatives.” This definition has been used to define a group of foreign-born people living in a more developed country who are now returning to their original homes for a visit. Recently, this definition has been called into question by a series of articles solicited by the ISTM in the Journal of Travel Medicine, arguing that for research and practical reasons, this definition no longer serves as clear a purpose, and may need to be revised. The risk concept rather than the ethnic background of the travelers is stressed. In this debate, Karin Leder will argue that the current definition is still serving a useful purpose, and Ron Behrens will contend that a change in definition is needed. Each speaker will present their argument for 20 minutes, after which David R Shlim will moderate a discussion between the speakers and the audience.

SY09
14:45-16:15
Symposium
Assessing Health Practices for International Travel: Knowledge, Attitudes, Practices and Realities
Chairs: Sarah Borwein, Hong Kong
Francesco Castelli, Italy

SY09.01 Global TravEpiNet: A Web-Based Data Collection Tool for Travel Medicine
Regina LaRocque, United States of America
- To describe the use of web-based data collection in a travel medicine network.
- To demonstrate the role of standardized electronic data for providing insight into the attitudes and practices of travel medicine providers.
- To review the use of TravEpiNet as a strategy for improving quality of pre-travel care.

SY09.02 High-Risk Travelers: Who Are They and What Can We Do to Address Their Travel Health Needs?
Elizabeth Barnett, United States of America
- To define types of high-risk travelers.
- To describe the differences in demographics and trip characteristics between high-risk and regular travelers.
- To suggest some strategies to address travel health needs of high-risk travelers.
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
</table>
| SY09.03    | Linking Travel Health Research Agenda to Evidence-Based Policy/Travel Health Recommendations  
Blaise Genton, Switzerland |                   |
|            | • To describe the process for identifying travel research questions in order to improve quality of pre- and post-travel services.  
• To demonstrate how research results can be used to improve the quality of travel health recommendations.  
• To explain the importance of using an evidence base derived from high quality research for guiding national and global guidelines for travel medicine. |                   |
| WS09       | Workshop                                                                | Ballroom C        |
| 14:45-16:15| Pharmacists and Travel Medicine  
Jeffery Goad, United States of America  
Larry Goodyer, United Kingdom |                   |
|            | • Describe the issues related to carrying medicines for personal use across international borders, with consideration of international policy and practice.  
• Describe how pharmacy travel medicines services are delivered worldwide and how this might affect its future development.  
• Identify the ethical, legal and practical issues regarding the delivery of pharmacy based travel medicine services. |                   |
| WS10       | Workshop                                                                | Room 302          |
| 14:45-16:15| Down Under - Oceania and Australasia (Destination)  
Peter Leggat, Australia  
Nick Zwar, Australia |                   |
| WS11       | Workshop                                                                | Room 306          |
| 14:45-16:15| Travel Health Resource Materials: Getting Answers / Orienting Staff / Keeping Current  
Gail Rosselot, United States of America  
Michele Sabourin, Canada |                   |
|            | • Identify at least 3 Internet and print resources to assist in the orientation of travel health clinic staff.  
• Describe a plan for researching traveler questions during the pre-travel assessment interview.  
• List at least 3 important resources to help clinicians maintain up-to-date travel health knowledge. |                   |
<p>| 16:15-17:00| Break/Exhibition                                                        | Auditorium        |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY10</td>
<td>Symposium</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>17:00-18:30</td>
<td>21st Century Tools for Migration Medicine: Mapping, Information Transfer and Technological Innovations in Interpreter Services</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: <em>Tomas Jelinek</em>, Germany <em>Kazunobu Ouchi</em>, Japan</td>
<td></td>
</tr>
<tr>
<td>SY10.01</td>
<td><em>Global Migration: Mapping of Past, Present, and Future Trends</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Martin Cetron</em>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the magnitude and nature of population movements.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List reasons for changes in the flow of migrants.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify how to access data about population movements and understand how this is mapped.</td>
<td></td>
</tr>
<tr>
<td>SY10.02</td>
<td><em>Information Transfer To and From Migrating Group</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>William Stauffer</em>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the nature and content of information transfer between areas sending and receiving migrants.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe how data is gathered in refugee camps and list how this data can inform providers after resettlement.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe how information gathered after resettlement can shape policies and activities before resettlement.</td>
<td></td>
</tr>
<tr>
<td>SY10.03</td>
<td><em>Technological Innovations in Interpreter Services</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Oscar Arocha</em>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe how medical interpreting evolved in the US and how it has improved access to care for our migrant population.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe how technology enhances access to language services.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify best practices in delivering language services.</td>
<td></td>
</tr>
<tr>
<td>WS12</td>
<td>Workshop</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>17:00-18:30</td>
<td><em>Travelers’ Diarrhea (ABC)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Charles Ericsson</em>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Valérie D’Acremont</em>, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the risk factors for acquisition of travelers’ diarrhea and whether they can be avoided.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the role of symptomatic relief medications, rehydration and changes in diet in the management of travelers’ diarrhea.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss how the largely bacterial causes of travelers’ diarrhea informs the use and choice of antimicrobial agents to cure the syndrome.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss how post diarrhea consequences like irritable bowel syndrome informs the controversial issue of whether to use antimicrobial agents to prevent travelers’ diarrhea.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| WS13 17:00-18:30 | Workshop Preparation of the Last Minute Traveler  
Deborah Mills, Australia  
Dominique Tessier, Canada | Ballroom C |
| WS14 17:00-18:30 | Workshop From Pruritus to Delusional Parasitosis  
Eric Caumes, France  
Jay Keystone, Canada | Room 302 |
| FC05 17:00-18:30 | Free Communications Dengue and Yellow Fever  
Chairs: Jacqueline Brezovski, Canada  
Dom Colbert, Ireland | Room 306 |
| 17:00-17:15 | FC05.01 Incidence of Dengue Virus Infection in Australian Travellers Visiting South and South East Asia  
Ratnam I., Black J., Leder K., Matchett E., Pollissard L., Luxemburger C., Demont C., Padaglione A., Woolley I., Panagiotidis T., Layden J., Gherardin T., Torresi J. | |
| 17:15-17:30 | FC05.02 Dengue Fever Outbreaks During 2009 - 2010 in Lima, Peru: Epidemiological Changes in Urban Areas  
Loayza M.J., Gloria A. Cisneros, Luis M. Chero, Juan C. Velasco, Gloria Yale, Reyna Aranda | |
| 17:30-17:45 | FC05.03 Dengue Virus Seroconversion in Travelers to Dengue-Endemic Areas  
| 17:45-18:00 | FC05.04 Yellow Fever: Information for Healthcare Professionals Advising Travelers — The First Web-based Yellow Fever Vaccine Training Course by US CDC  
Gershman M.D., Sommers T., Staples J.E., Schwartz T.A., Bair-Brake H., Kozarsky P., Holton K., Brunette G., Gallagher N. | |
| 18:00-18:15 | FC05.05 Evaluation of the Impact of a National Training Programme on Yellow Fever Vaccination Practice in England, Wales and Northern Ireland  
Boddington N., Simons H., Launders N.B., Hill D.R. | |
| 18:15-18:30 | FC05.06 Delayed Antibody Response to Yellow Fever Vaccination in Elderly Coincides with Prolonged Viraemia  
Roukens A.H., Soonawala D., Joosten S.A., de Visser A.W., Jiang X., Bredenbeek P.J., van Dissel J.T., Visser L.G. | |
CISTM12 Program  Wednesday, 11 May 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-17:00</td>
<td>Congress Registration</td>
<td>Auditorium Pre-function</td>
</tr>
<tr>
<td>MTH3</td>
<td>Meet the History 3&lt;br&gt;What I Caught at the ISTM&lt;br&gt;Betsy Wade, United States of America</td>
<td>Room 302</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>MTP3&lt;br&gt;Meet the Professor 3&lt;br&gt;Hans Dieter Nothdurft, Germany</td>
<td>Room 304</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>COD3&lt;br&gt;Case of the Day 3&lt;br&gt;Rudy Zimmer, Canada</td>
<td>Room 306</td>
</tr>
<tr>
<td>PL03</td>
<td>Plenary&lt;br&gt;The Immunocompromised Traveller&lt;br&gt;Chairs: David Freedman, United States of America Leo Visser, The Netherlands</td>
<td>Ballroom A-C</td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>PL03.01 Overview for the Travel Medicine Specialist:&lt;br&gt;Immunosuppression, Immunosuppressive Agents, and Drug Interactions&lt;br&gt;CN Kotton, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Knows the basic mechanisms of an immune response to vaccines.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Knows in what way and for how long different immunosuppressive agents, including immunobiologicals, affect the immune response to a vaccine.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Can determine the level of immunosuppression in a traveler on immunosuppressive drugs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Knows which drug interactions between immunosuppressive drugs and travel-related drugs are relevant.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Knows which infections to expect in the different types of immunosuppression.</td>
<td></td>
</tr>
<tr>
<td>PL03.02</td>
<td>Vaccine Use in Immunocompromised Travelers&lt;br&gt;Edward T. Ryan, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Can translate knowledge of immunosuppressive agents into advice on vaccine use.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Knows when it is safe to give yellow fever vaccine and when it is not.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Knows when it is useful to determine antibody levels after vaccination in a immunocompromized host.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Knows which additional preventive measures are indicated and useful in immunosuppressed travelers.</td>
<td></td>
</tr>
<tr>
<td>PL03.03</td>
<td>Case-Based Discussions&lt;br&gt;Robert Orenstein, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learns from case-based discussion how to apply this knowledge in daily practice</td>
<td></td>
</tr>
<tr>
<td>Program</td>
<td>Location</td>
<td>Time</td>
</tr>
<tr>
<td>----------</td>
<td>----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>10:30-11:15</td>
<td>Break/Exhibition</td>
<td>Auditorium</td>
</tr>
<tr>
<td>SY11</td>
<td>Symposium</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td>Self-Management During Travel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Charles Ericsson, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Martin Haditsch, Austria</td>
<td></td>
</tr>
</tbody>
</table>

SY11.01 *Diarrhea Management Abroad*

**Santanu Chatterjee, India**

- Describe practical messages for Travel Health Advisors on limiting diarrhoeal risk - should ‘cook it, peel it, boil it or forget it’ be forgotten?
- Describe basics of diarrhoea self-management during travel - what to treat and how to treat?
- List core issues in accessing health care while abroad - when to seek and whom to seek?

SY11.02 *Fever During Travel: What to do?*

**Alberto Matteelli, Italy**

- Identify the clinical situations which may present with fever during travel, with consideration of risk taking behaviours, incubation times and other factors.
- Describe to travelers the basic principles to identify when fever may represent a sign of alert for a potential medical emergency and how to access medical care abroad, including suggesting the respective tests.
- Describe to travelers the key messages on how to manage fever associated syndromes when a medical emergency has been excluded.

SY11.03 *E+C=MQ²: Drug Interactions with Anti-Malarials*

**Patricia Schlagenhauf, Switzerland**

- List the practical key messages on drug interactions which advisors should convey to travelers with regard to drugs used and not to be used.
- Communicate the basic principles of avoiding drug interactions.
- Explain what travelers should know and do in case they need to take potentially interacting drugs.

SY12     | Symposium       | Ballroom A   |
| 11:15-12:45 | Travel Medicine Pharmacology |            |
|          | Chairs: Richard Dawood, United Kingdom |            |
|          | Deborah Nicolls Barbeau, United States of America |            |

SY12.01 *How to Approach Drug-Drug Interactions*

**Alan Magill, United States of America**
**SY12.02 Travel Related Drug Interactions**  
**Caroline Zeind**, United States of America

- Identifies what to advise in a traveler who is on chronic medication and who needs an antimalarial.
- Identifies what to advise in a traveler who is on chronic medication and who needs an antibiotic.
- Lists which drug-drug combinations should be avoided.

**SY12.03 Interactions with HIV Drugs**  
**David Burger**, The Netherlands

- Describes the most important metabolic pathways of anti-retroviral drugs.
- Identifies the clinical relevant drug-drug interactions with antibiotics and hiv drugs.
- Identifies the clinical relevant drug-drug interactions with antimalarials and hiv drugs.
- Describes how to advice on drug-drug interactions in patients on hiv drugs.

**WS15**  
**Workshop**  
11:15-12:45  
**Travel Medicine and Neurology**  
**Gerd Dieter Burchard**, Germany  
**Maria Mileno**, United States of America

- Identify the most common infectious neurologic issues in tropical medicine and travel medicine.
- List the most important differential diagnoses in meningoencephalitis, myelitis and space-occupying lesions of the brain in travellers and migrants.
- List the correct diagnostic tests to order for parasitic diseases of the CNS in travellers and migrants.

**WS16**  
**Workshop**  
11:15-12:45  
**The Pediatric Traveler**  
**Ralf Bialek**, Germany  
**Shiela Mackell**, United States of America

**FC06**  
**Free Communications**  
**Clinical Issues/Post Travel**  
11:15-12:45  
**Chairs: Robert Dedmon**, United States of America  
**Alexandra Grieve**, United Kingdom

**11:15-11:30**  
**FC06.01 Diagnostic Trends Over 10 Years Among Travelers Returning to GeoSentinel Sites**  
11:30-11:45  FC06.02  Travel-Related Morbidity in Children: a Prospective Observational Study  
van Rijn S.F., Driessen G., Overbosch D., van Genderen P.J.

11:45-12:00  FC06.03  Travel-associated Illness in Older Adults (> 60 years)  
Gautret P., Gaudart J., Leder K., Schwartz E., Castelli F., Lim P.L., Murphy H., Keystone J., Cramer J., Shaw M., Boddaert J., von Sonnenburg F., Parola P., GeoSentinel

12:00-12:15  FC06.04  Importation and Spread of Panton-Valentine Leukocidin Positive Staphylococcus Aureus Through Nasal Carriage and Skin Infections in Travelers to the Tropics and Subtropics  
Zanger P., Schulte B., Scherbaum H., Schleucher R., Wolz C., Kremsner P.G.

12:15-12:30  FC06.05  Update of Practice Guidelines for Fever in Returning Travelers and Migrants on the Basis of a Systematic Review and a Validation Study  
Rossi I.A., Mueller Y., Burnand B., Genton B., D’acremont V.

12:30-12:45  FC06.06  Post-travel Screening of Long-term Travelers to the Tropics for Intestinal Parasites Using Molecular Diagnostics  

12:45-14:45  Lunch Break

SY13  Symposium  
Malaria  
Ballroom B

14:45-16:15  SY13.01  Treatment of P Vivax Malaria  
Kevin Baird, United States of America

- Define the basic strategy for radical cure of acute P. vivax malaria attacks in different endemic settings.
- List treatment pitfalls with primaquine, the only therapeutic option against relapsing forms called hypnozoites.
- Be able to recognize and manage treatment failures of P. vivax infections.

SY13.02  Doxy, Mefloquine or Malarone?  
Thomas Löschner, Germany

- List the drug options for chemoprophylaxis.
- To assess the importance of adverse effects of the three main options, mefloquine, atovaquone-proguanil and doxycyclin.
- Identify the options of changing the malaria protection measures while experiencing adverse events of chemoprophylaxis during travel.
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>SY13.03 Where Are We Going?</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Louis Loutan, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the options of malaria protection in a changing (i.e. declining)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>transmission epidemiology worldwide,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the concepts of malaria protection beyond chemoprophylaxis,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>respecting the weight of pros and cons,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To assess the value of visionary concepts of malaria protection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in the light of other arthropod borne infections among travelers.</td>
<td></td>
</tr>
<tr>
<td>WS17</td>
<td><strong>Workshop</strong></td>
<td>Ballroom A</td>
</tr>
<tr>
<td>14:45-16:15</td>
<td>How to Start a Travel Clinic (ABC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Karen Avery, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cate Riley, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss the need for Travel Medicine specific education.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the medical legal aspects of running a Travel Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>service.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ensure an awareness of reliable sources of information.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the multiple factors involved in establishing a Travel Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>service.</td>
<td></td>
</tr>
<tr>
<td>WS18</td>
<td><strong>Workshop</strong></td>
<td>Ballroom C</td>
</tr>
<tr>
<td>14:45-16:15</td>
<td>Travel Medicine in the Military</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adriaan Hopperus Buma, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patrick Hickey, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the specific travel medicine requirements for the military</td>
<td></td>
</tr>
<tr>
<td></td>
<td>during deployment.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the specific travel medicine approach for the military</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in the post-deployment phase.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the different approaches and coordination within</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a multinational taskforce.</td>
<td></td>
</tr>
<tr>
<td>WS19</td>
<td><strong>Workshop</strong></td>
<td>Room 302</td>
</tr>
<tr>
<td>14:45-16:15</td>
<td>Training to Essential Immunization Competencies in Travel Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fiann Crane, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claire Wong, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe and access the published core immunization</td>
<td></td>
</tr>
<tr>
<td></td>
<td>competencies as identified by expert bodies including</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Center for Disease Control (CDC), USA, Public Health Agency of Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(PHAC), Canada, and Health Protection Agency (HPA), UK.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss the importance of quality immunization education</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to enhance patient care and avoid the negative consequences</td>
<td></td>
</tr>
<tr>
<td></td>
<td>of inadequate provider preparation.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the available tools designed to support vaccine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>provider education.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
</tbody>
</table>
| FC07 14:45-16:15 | Free Communications Challenges and Controversies in Rabies, JE and Hepatitis B  
Chairs: Philip Fischer, United States of America  
Gerard Sonder, The Netherlands | Room 306     |
| 14:45-15:00  | FC07.01 Risk of Possible Exposure to Rabies Among Travelers from Developed Countries in Southeast Asia  
Piyaphanee W., Kititrakul C., Sibunruang S., Charoenpong P., Olanwitjitwong J., Ponam T., Kerdari P., Tangkanakul W., Tantawichien T. | Room 306     |
| 15:00-15:15  | FC07.02 Do Travelers Receive Timely and Adequate Rabies Post-exposure Prophylaxis?  
Uwanyiligira M., Landry P., Genton B., de Valliere S. | Room 306     |
| 15:15-15:30  | FC07.03 The Immunogenicity of a Modified Intradermal Pre-exposure Rabies Vaccination Schedule — A Case Series of 420 Travellers  
Mills D., Lau C., Fearnley E., Weinstein P. | Room 306     |
| 15:30-15:45  | FC07.04 What is Known About the Protective Efficacy of Rabies Vaccine in Humans? An Unexpected Result From an Immunogenicity Study of Pre-Exposure Rabies Vaccination of Healthy Volunteers  
Horowitz A., Horton D.L., Goddard T., Riley E.M., Behrens R.H. | Room 306     |
| 15:45-16:00  | FC07.05 Safety, Immunogenicity and Dose Confirmation for the Inactivated Japanese Encephalitis Vaccine IXIARO®, IC51, in Filipino Children aged 3 to 12 years  
| 16:00-16:15  | FC07.06 High Response Rate in Previous Non-responders After Revaccination with High Potent Hepatitis B Vaccines  
<p>| 16:15-17:15  | Break/Exhibition/Poster Session (Authors in Attendance) | Auditorium   |
| 17:15-18:45  | Membership Assembly                                                     | Ballroom A   |
| 18:45-10:30  | Cocktail Reception for ISTM Members                                      | Ballroom A   |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-14:00</td>
<td>Congress Registration</td>
<td>Auditorium Pre-function</td>
</tr>
<tr>
<td>MTP4</td>
<td>Meet the Professor 4</td>
<td>Room 302</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>Fiona Genasi, United Kingdom</td>
<td>Room 302</td>
</tr>
<tr>
<td>COD4</td>
<td>Case of the Day 4</td>
<td>Room 306</td>
</tr>
<tr>
<td>08:00-08:45</td>
<td>Jesse Alves, Brasil</td>
<td>Room 302</td>
</tr>
<tr>
<td>SY14</td>
<td>Symposium</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>Prepare Relief Workers and Students</td>
<td>Ballroom B</td>
</tr>
<tr>
<td></td>
<td>Chairs: Suni Boraston, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eyal Leshem, Israel</td>
<td></td>
</tr>
<tr>
<td>SY14.01</td>
<td>Disaster Relief Preparations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kirsten Johnson, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the most relevant planning issues concerning disaster relief measures.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Appreciate the practical preparations implied in disaster relief.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Be able to assess necessary adaptations in action during disaster relief projects.</td>
<td></td>
</tr>
<tr>
<td>SY14.02</td>
<td>Preparing Health Care Workers for Resource Limited Settings, Including HIV</td>
<td>Ballroom B</td>
</tr>
<tr>
<td></td>
<td>Philippe Calain, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the technical and contextual constraints faced by health care workers in the practice of humanitarian medicine.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List classical sources of psychological and moral tensions to which health care workers are exposed in resource-limited settings.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Be able to outline programmatic priorities for HIV/AIDS management in high prevalence contexts.</td>
<td></td>
</tr>
<tr>
<td>SY14.03</td>
<td>Traveling Students</td>
<td>Ballroom B</td>
</tr>
<tr>
<td></td>
<td>Howard Heller, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the key points of information conveyed to students before a working stay abroad under limited conditions.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the potential problems encountered by students during clinical working stays abroad.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To compile a checklist of travelling students for their working stays in Asia, Africa and Latin America.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>WS20</td>
<td>Workshop</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>09:00-10:30</td>
<td><strong>Sex, Gender and Travel Medicine</strong> &lt;br&gt;Lin Chen, United States of America &lt;br&gt;Patricia Schlagenhauf, Switzerland</td>
<td></td>
</tr>
</tbody>
</table>
|          | • Describe the sex differences in the patterns of acquired travel related diseases.  
|          | • Recognise gender/sex dependant responses to vaccines and travel medicine medications.  
|          | • Describe how to subtly adjust pre-travel health advice to address the different needs of men and women. |              |
| FC08     | Free Communications <br>**Late Breaking Free Communications** <br>Chairs: Winnie Ooi, United States of America | Ballroom C   |
| 09:00-10:30 | **FC08.01 Characteristics and Spectrum of Disease among Ill Travelers Returning from Post-Earthquake Haiti: The GeoSentinel Experience** <br>Doug Esposito, United States of America |              |
|          | • Identify the demographic characteristics of ill travelers returning from Haiti in the year post the 2010 earthquake.  
|          | • List the spectrum of disease among travelers returning from post-earth Haiti who are seen at a GeoSentinel sites.  
|          | • Communicate the implications for pre travel preparation and post travel evaluation |              |
|          | **FC08.02 Cholera Vaccines: Do They Have a Role in Outbreak Settings?** <br>Edward T. Ryan, United States of America |              |
|          | • Describe currently available cholera vaccines.  
|          | • Define their potential benefits in (1) endemic zones, (2) preemptively in predictable settings, and (3) reactive use in an outbreak setting (list the benefits and risks).  
|          | • Identify obstacles and side effects of their use. |              |
|          | **FC08.03 Yellow Fever Outbreak in Uganda** <br>Jeffrey Miller, United States of America |              |
|          | • Discuss the approach to and complexity of determining the outbreak etiology.  
|          | • Identify the epidemiological and clinical characteristics of yellow fever cases identified during the outbreak in Uganda.  
|          | • List approaches to its control and implications for the pre-travel preparation of travelers to Uganda. |              |
### FC08.04 Quadrivalent Meningitis Vaccination in Children
**Gerd Dieter Burchard, Germany**

- List the ages to administer vaccine and special circumstances.
- Discuss the benefit of meningitis vaccine in children.
- Name proper administration and site.

### FC08.05 Aussie Disaster
**Joseph Torresi, Australia**

- Identify the epidemiology and clinical syndromes of arboviral infections associated with flooding in the tropical north and the Southern states of Australia.
- Identify the epidemiology and clinical syndromes of bacterial infections that follow the annual wet season and flooding associated with cyclones in the north of Australia.
- Describe the geographical distribution of flood associated arboviral and bacterial infections.

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:45</td>
<td><strong>Break</strong></td>
<td>Boylston Hallway</td>
</tr>
<tr>
<td>10:45-12:15</td>
<td><strong>Plenary</strong>&lt;br&gt;<strong>Emerging Economies: Changes in Travel Patterns and Differences for Pre-Travel</strong>&lt;br&gt;<strong>Chairs:</strong> Christina Greenaway, Canada&lt;br&gt;Robert Steffen, Switzerland</td>
<td>Ballroom A-C</td>
</tr>
<tr>
<td></td>
<td><strong>PL04.01 Changing Travel Patterns from Emerging Economies</strong>&lt;br&gt;<strong>Poh Lian Lim, Singapore</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the changing travel patterns from emerging economies.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recall how they differ from traditional travel patterns.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the reasons for changing travel patterns.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL04.02 Travel from Emerging Economies in South America. Implications for Travel Medicine Providers</strong>&lt;br&gt;<strong>Cecilia Perret, Chile</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recall the rate and pattern of uptake of pre-travel advice and travel behaviour of travellers from South America.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the most frequent travel destinations of these travelers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the epidemiology of travel-related health problems in these travelers.</td>
<td></td>
</tr>
<tr>
<td>12:15-13:00</td>
<td><strong>Closing Activities</strong></td>
<td>Ballroom A-C</td>
</tr>
</tbody>
</table>
Exhibits and Posters

The Exhibits, Posters, Coffee Breaks and Internet Café are located in the Auditorium 2nd Floor John B. Hynes Veterans Memorial Convention Center.

- Key companies offering State-of-the-Art products and services

Exhibits hours:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monday, 9 May 2011</strong></td>
<td></td>
</tr>
<tr>
<td>Exhibits and Posters</td>
<td>10:30-17:00</td>
</tr>
<tr>
<td>Coffee Breaks</td>
<td>10:30-11:15</td>
</tr>
<tr>
<td></td>
<td>16:15-17:00</td>
</tr>
<tr>
<td><strong>Tuesday, 10 May 2011</strong></td>
<td></td>
</tr>
<tr>
<td>Exhibits and Posters</td>
<td>10:30-17:00</td>
</tr>
<tr>
<td>Coffee Breaks</td>
<td>10:30-11:15</td>
</tr>
<tr>
<td></td>
<td>16:15-17:00</td>
</tr>
<tr>
<td><strong>Wednesday, 11 May 2011</strong></td>
<td></td>
</tr>
<tr>
<td>Exhibits</td>
<td>10:30-17:30</td>
</tr>
<tr>
<td>Coffee Breaks</td>
<td>10:30-11:15</td>
</tr>
<tr>
<td></td>
<td>16:15-17:00</td>
</tr>
<tr>
<td><strong>Wednesday, 11 May 2011</strong></td>
<td></td>
</tr>
<tr>
<td>Poster Session/Authors in Attendance</td>
<td>16:15-17:15</td>
</tr>
<tr>
<td><strong>Thursday, 12 May 2011</strong></td>
<td></td>
</tr>
<tr>
<td>Coffee Break</td>
<td>10:30-10:45</td>
</tr>
</tbody>
</table>

All Scientific Sessions will be located in Ballroom A-C and Rooms 302, 304, and 306 of the John B. Hynes Veterans Memorial Convention Center.
<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adventure Medical Kits</td>
<td>500</td>
</tr>
<tr>
<td>Air Ambulance Card</td>
<td>307</td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention</td>
<td>203</td>
</tr>
<tr>
<td>Clasado Ltd</td>
<td>302</td>
</tr>
<tr>
<td>Crucell Vaccines</td>
<td>100</td>
</tr>
<tr>
<td>Crucell</td>
<td>11</td>
</tr>
<tr>
<td>GermBana, Inc</td>
<td>106</td>
</tr>
<tr>
<td>HealthMap; Children’s Hospital Boston</td>
<td>107</td>
</tr>
<tr>
<td>International Society for Infectious Diseases</td>
<td>201</td>
</tr>
<tr>
<td>MEDEX Global Solutions</td>
<td>506</td>
</tr>
<tr>
<td>NECTM4 2012, Hosted by Travel Medicine Society of Ireland</td>
<td>502</td>
</tr>
<tr>
<td>Novartis Vaccines</td>
<td>313</td>
</tr>
<tr>
<td>Oxford University Press</td>
<td>300</td>
</tr>
<tr>
<td>PharmaJet, Inc</td>
<td>214</td>
</tr>
<tr>
<td>Public Health Agency of Canada, Travel Health Division</td>
<td>202</td>
</tr>
<tr>
<td>Royal College of Physicians and Surgeons of Glasgow</td>
<td>103</td>
</tr>
<tr>
<td>Sanofi Pasteur</td>
<td>312</td>
</tr>
<tr>
<td>Shoreland Inc</td>
<td>206</td>
</tr>
<tr>
<td>SIGMA-TAU S.p.A Head Office &amp; Research Centre</td>
<td>101</td>
</tr>
<tr>
<td>Theramed</td>
<td>14</td>
</tr>
<tr>
<td>Travel Health 101 LLC</td>
<td>200</td>
</tr>
<tr>
<td>Travel Medicine, Inc</td>
<td>212</td>
</tr>
<tr>
<td>Traveler’s Supply Inc</td>
<td>301</td>
</tr>
<tr>
<td>Wiley-Blackwell</td>
<td>213</td>
</tr>
</tbody>
</table>
For over twenty years, Adventure Medical Kits has been the leading manufacturer of travel medical kits used around the globe. Drawing on the experience of wilderness and travel medicine pioneer, Dr. Eric A. Weiss, AMK products provide hospital-quality supplies and essential medical information to keep travelers safe and healthy on trips of any length.

For your patients who travel internationally, visit Crucell Vaccines at BOOTH 100 to learn about the many advantages and benefits of using the oral typhoid vaccine - VIVOTIF® (Typhoid Vaccine Live Oral Ty21a). You can also pick up complimentary educational literature and reminder tools for your patients.

GermBana™ products are made from our proprietary fabric Fibrant™ which kills germs on contact and inhibits bacterial growth without the use of chemicals. All products are washable and reusable without affecting the germ killing properties. Initial products include face gator, scarf or neck wrap, and gloves for consumer, with worldwide distribution.
Booth # 107
**HealthMap; Children’s Hospital Boston**
1 Autumn Street; Informatics; AU 451
Boston, MA 02115
Tel: (1) 857-218-4079
Fax: (1) 617-730-0267
Email: amy.sonricker@childrens.harvard.edu
Website: www.healthmap.org

HealthMap.org is a freely available Website that delivers real-time intelligence on a broad range of emerging infectious diseases for a diverse audience. HealthMap brings together disparate data sources to achieve a unified, comprehensive view of the current global state of infectious diseases and their effect on human and animal health.

Booth # 201
**International Society for Infectious Diseases**
9 Babcock Street
Brookline MA 02446 USA
Tel: (1) 617-277-0551
Fax: (1) 617-278-9113
Email: info@isid.org
Website: www.isid.org

ISID is an educational non-profit organization with over 30,000 members worldwide. Its objectives are to promote communication among those engaged in all aspects of infectious diseases. These goals are achieved through international scientific meetings, exchange fellowships, grants for infection control programs, a newsletter, and the International Journal of Infectious Diseases.

Booth # 506
**MEDEX Global Solutions**
8501 LaSalle Road, Suite 200
Towson, MD 21286 USA
Tel: (1) 410-453-6300
Fax: (1) 410-453-6301
Email: info@medexglobal.com
Website: www.medexglobal.com

MEDEX provides emergency medical and security evacuations, international travel insurance, and destination intelligence. Supported by our in-house 24/7 Emergency Response Center and a network of 59,000 providers. For 30 years, more than 13 million travelers have relied on MEDEX for comprehensive international medical insurance and assistance. Custom programs available.

Booth # 502
**NECTM4 2012, Hosted by Travel Medicine Society of Ireland**
17, Lowtown Manor, Robertstown, NAAS, Co. Kildare, Ireland
Tel: +353 45 890 127
Email: anneredmond@eircom.net
Website: www.tmsi.ie

The NECTM4 conference will bring together travel medicine practitioners, researchers, and individuals from related specialties under one roof. In addition to the scientific programme, the conference provides the opportunity to network with colleagues and form new collaborations. Also the special workshops on controversial topics will offer opportunities for vibrant discussions.

Booth # 313
**Novartis Vaccines**
350 Massachusetts Avenue
Cambridge, MA 02139 USA
Tel: (1) 617-871-7000
Fax: (1) 617-871-8911
Email: nvd.communications@novartis.com
Website: www.novartisvaccines.com

At Novartis Vaccines and Diagnostics, we believe that caring for patients begins with protecting individuals and societies from infection in the first place. Our innovative vaccines and diagnostics tools are designed to prevent the spread of life-threatening diseases in order to protect vulnerable populations and keep healthy people healthy.

Booth # 300
**Oxford University Press**
198 Madison Avenue
New York, NY 10016 USA
Tel: (1) 800-451-7556
Fax: (1) 919-677-1303
Email: custserv.us@oup.com
Website: www.oup.com/us

The “Yellow Book” is back in a new edition! Visit the Oxford University Press booth to order your copy of the CDC HEALTH INFORMATION FOR INTERNATIONAL TRAVEL 2012 at a special introductory price.
Exhibitors

Booth # 214
PharmaJet, Inc.
400 Corporate Circle, Suite N
Golden, CO 80401 USA
Tel: (1) 303-526-4278
Fax: (1) 303-526-4052
Email: todd@pharmajet.com
Website: www.pharmajet.com

PharmaJet Needle-free injection technology is FDA-cleared for the 0.5mL deliver of all vaccines and liquid medications, both intramuscular and subcutaneous. Developed under WHO guidelines, ISO certified, CE Marking, it is simple, cost effective, with an auto-disable one-time-use syringe. Unique filling adapter saves two doses per vial.

Booth # 202
Public Health Agency of Canada,
Travel Health Division
380 Hunt Club Road, A.L. 5902
Ottawa, Ontario K1A OK9 Canada
Website: www.travelhealth.gc.ca

The Public Health Agency of Canada’s Travel Health Division provides information resources for the public and health care professionals. Visit www.travelhealth.gc.ca for resources that include travel health-related statements and recommendations, travel health notices, fact sheets on specific diseases and health conditions, as well as information on yellow fever vaccination centres.

Booth # 103
Royal College of Physicians and Surgeons of Glasgow
232-242 St. Vincent Street
Glasgow G2 5RJ Scotland
Tel: +44 141 221 6072
Fax: +44 141 221 1804
Email: muir.brown@rcpsg.ac.uk
Website: www.rcpsg.ac.uk

The Royal College of Physicians and Surgeons of Glasgow is an educational institution, membership organization and charity. With more than 10,000 members worldwide, the College is a multi-disciplinary standard setting body, and home to a Faculty of Travel Medicine, supporting medical and non-medical specialists in the field.

Booth # 312
Sanofi Pasteur
Discovery Drive
Swiftwater, PA 18370 USA
Tel: (1) 800-822-2463
Email: kim.quinn@sanofipasteur.com
Website: www.sanofipasteur.us

Sanofi Pasteur, Inc., the vaccines division of sanofi-aventis Group, provides pediatric, adult, and travel vaccines for diseases such as diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, influenza, rabies, Japanese encephalitis, typhoid fever, yellow fever, and meningococcal disease. To learn more about our products, visit our exhibit.

Booth # 206
Shoreland Inc.
P.O. Box 13795
Milwaukee, WI  53213-0795 USA
Tel: (1) 414-290-1900
Fax: (1) 414-290-1907
Email: sales@shoreland.com
Website: www.shoreland.com

Shoreland Travax® is a web-based resource meeting the global health and safety information needs of travel medicine practitioners and medical managers. Shoreland editors and medical advisors turn up-to-date data into the information you require to make the care and counseling decisions you face with your patients and your personnel abroad.

Booth # 101
SIGMA-TAU S.p.A, Head Office & Research Centre
via Pontina Km. 30,400
Pomezia (Rome) 00040 Italy
Tel: +39 06 9139
Fax: +39 06 9139 3980
Website: www.sigma-tau.it

Sigma-Tau is a leading research-based Italian pharmaceutical company, with annual revenues of £ 673 million in 2010 and over 2400 employees worldwide. Therapeutic areas in which the company’s research and development are focused, in particular, on oncology, immunology and on rare, neglected, and/or high social impact diseases such as malaria, but its strong experience and know-how in the cardiovascular, nervous system, and metabolic disease areas are also very important assets. Sigma-Tau has operating subsidiaries throughout Europe, US and Asia and maintains a presence in all of the world’s major pharmaceutical markets.
Exhibitors

Booth # I 4
Theramed
6891 Edwards Blvd.
Mississauga, Ontario L5T 2T9 Canada
Tel: (1) 800-305-4441 ext. 232
Fax: (1) 888-633-3644
Email: ataylor@theramed.com
Website: http://theramed.com

Theramed specializes in licensing and acquiring new and existing medications. By partnering with domestic and international pharmaceutical/biotechnology companies, we successfully commercialize their products in Canada. Theramed has both full-service warehouse and distribution capabilities. We work to conduct comprehensive regulatory & scientific affairs as well as professional sales & marketing expertise.

Booth # 200
Travel Health 101 LLC
PO Box 2154
Albany, NY 12220 USA
Tel: (1) 914-219-1918
Email: lbunnell@travelhealth101.com
Website: www.travelhealth101.com

Travel Health 101 LLC offers 2 products for travel healthcare providers: 1) a time-saving audio/visual educational presentation that can be shown online to travelers in clinics and/or on their own computers and 2) a 5-CME online introductory course for training new staff on how to provide pre-travel care.

Booth # 212
Travel Medicine, Inc.
369 Pleasant Street
Northampton, MA 01060 USA
Tel: (1) 413-584-0381
Fax: (1) 413-584-6656
Email: stuartrose1@gmail.com
Website: www.travmed.com

Travel Medicine, Inc. offers a range of supplies designed to enhance the health, comfort and safety of those venturing abroad, especially to lesser-developed countries. Many Travel Clients refer their clients to our Website (www.travmed.com), a reliable source of essential products often recommended to help prevent travel-related illness.

Booth # 301
Traveler’s Supply Inc.
2024R Westover Road
Chicopee, MA 01022 USA
Tel: (1) 866-662-2483 / (1) 413-593-8941
Fax: (1) 413-593-2751
Email: jim@travelerssupply.com
Website: www.travelerssupply.com

Traveler’s Supply, carries 3MUltrathon & Duration Permethrin Insect Repellents. We offer the only 10% Permethrin Concentrate and a full line of custom medical, dental and needle kits, NEW FLAVORED ORS and Go-Girl’s. We are the exclusive supplier of the Duration Mosquito Guard Netting the longest lasting net on the market.

Booth # 213
Wiley-Blackwell
111 River Street
Hoboken, NJ 07030 USA
Tel: (1) 877-762-2974
Fax: (1) 800-597-3299
Email: wileycustomer@wiley.com
Website: www.wiley.com

Wiley publishes an enormous range of top quality consumer, professional, educational and research material. Wiley-Blackwell, the scientific, technical, medical and scholarly publishing business of John Wiley & Sons, is the leading society publisher and offers libraries peer-reviewed primary research and evidence based medicine across 1250 online journals, books, reference works and databases.
Abstracts Poster Presentations

Vectorborne Infections (Malaria, Dengue, etc.)

PO01.01
Safety and tolerability of a short higher-dose primaquine regimen for terminal prophylaxis in healthy subjects
Ebringer A.A.1, Edstein M.D.1, Shanks D.I, Baker J.1
1Australian Army Malaria Institute, Clinical Studies and Surveillance, Enoggera, Australia

PO01.02
Subcutaneous Nodule Caused by Dirofilaria repens
Kotar T.1, Knez L.1, Stallowsky B.1, Vincek K.1, Logar J.2, Lejko Zupanc T.1, Sekcija za tropsko in potovalno medicino Slovenija
1University Clinical Center Ljubljana, Department of Infectious diseases, Ljubljana, Slovenia, 2Medicinska fakulteta Univerze v Ljubljani, Inštitut za mikrobiologijo in imunologijo, Ljubljana, Slovenia

PO01.03
African Tick-bite Fever Infection in Travellers Returning from South-Africa
Wieten R.1, Hovius J.W.1, Tijssse-Klasen E.2, Sprong H.2, Grobusch M.P.1
1Academic Medical Centre, Amsterdam, Netherlands, 2National Institute of Public Health and the Environment (RIVM), Bilthoven, Netherlands

PO01.04
Mass blood Sampling of Malaria Cases, Gulyial Union Council District Attock .2010
Kumar P.1
1Field Epidemiology and Laboratory Training Program Pakistan, Public Health, Rawalpindi, Pakistan

PO01.05
Effectiveness of artemether/lumefantrine for the treatment of Plasmodium vivax malaria in young children in Papua New Guinea
Senn N.1,2,3, Rarau P.3, Mueller I.1, Genton B.1,5
1Swiss Tropical and Public Health Institute, Basel, Switzerland, 2University of Basel, Basel, Switzerland, 3PNG Institute of Medical Research, Madang, Papua New Guinea, 4Walter and Eliza Hall Institute, Melbourne, Australia, 5Travel Clinic, Department of Ambulatory Care and Community Medicine, Division of Infectious Diseases, University Hospital, Lausanne, Switzerland

PO01.06
Dengue fever outbreak in Dar es Salaam and Zanzibar in May-July 2010. Background: Up till recently dengue fever was not a common infectious disease in Tanzania and East Africa. This report describes a small outbreak of dengue suspect cases seen in April-July 2011, during a heavy rainy season, in a private clinic in Dar es Salaam Tanzania.
Klaassen B.1, Assenga E.1, Van Gorp E.C.M.2, Martina B.E.E.3
1IST medical Cheme Clinic, Dar es Salaam, Tanzania, United Republic of, 2Erasmus University, Virology, Rotterdam, Netherlands, 3Erasmus University, Virology, unit Exotic Viruses, Rotterdam, Netherlands

PO01.07
TBE and Travellers: Obstacles and Misconceptions of Prevention and the Role of Vaccination
Haditsch M.1,2, Kunze M.2, International Scientific Working Group on Tick Borne Encephalitis (ISW-TBE)
1TravelMedCenter, Leonding, Austria, 2Labor Hannover MVZ GmbH, Hannover, Germany, 3Medical University of Vienna, Institute for Social Medicine and Public Health, Vienna, Austria
PO01.08  
**A 5-year itch**  
Goorhuis A.1, van Vuig M.1, Grobusch M.P.1  
1Academic Medical Center, Tropical diseases, Amsterdam, Netherlands

PO01.09  
**Yellow Fever Vaccination Centres in Canada and the Relevance to Canadian International Travellers**  
Bryson M.1, Sivaraj C.1, Geduld J.1  
1Public Health Agency of Canada, Infectious Disease Prevention and Control Branch, Ottawa, Canada

PO01.10  
**Prognostic Relevance of *P. falciparum* Malaria Thrombocytopenia in Adult Travelers**  
Rapp C.1, Diop E.1, Mayet A.1, Aoun O.1, Ficko C.1, Andriamanantena D.1, Imbert P.1  
1HIA Begin, Infectious and tropical diseases, Saint-Mandé, France

PO01.11  
**Imported cases of Dengue Fever diagnosed in metropolitan France : Protective measures, health care itinerary and outcome**  
Rapp C.1, Andriamanantena D.1, Ficko C.1, Aoun O.1, Bigaillon C.2, Imbert P.1, Mérens A.3  
1HIA Begin, Infectious and Tropical diseases, Saint-Mandé, France, 2HIA Begin, Department of Biology, Saint-Mandé, France, 3HIA Begin, Departament of biology, Saint-Mandé, France

PO01.12  
**A severe and late Plasmodium ovale Infection in an Adult returning from Cote d’Ivoire**  
Aoun O.1, Lambert Y.2, Rapp C.1, Moriconi M.2, Arnaud B.2, Roze B.2  
1HIA Begin, Infectious and tropical diseases, Saint-Mandé, France, 2Centre hospitalier général, internal medicine, Quimper, France

PO01.13  
**Two cases of Late Plasmodium ovale Acute Primary Infection in Travelers**  
Mellon G.1, Rapp C.1, Aoun O.1, Andriamanantena D.1, Ficko C.1, Dutasta F.1, Imbert P.2  
1HIA Begin, Infectious and tropical diseases, Saint-Mandé, France, 2HIA Begin, Infectious and tropical diseases, Saint-Mandé, France

PO01.15  
**Malaria Risk Area Traveller’s, with Prior Stays Oporto’s International Vaccination Centre**  
Saldanha M.G.1, Oporto International Vaccination Centre Group  
1Oporto International Vaccination Centre, Porto, Portugal

PO01.16  
**Malaria among patients consulting a primary healthcare center in Leogane, Haiti**  
Neuuberger A.1, Zeolan O.1, Shiri T.1, Pex R.1, Urman M.1, Held K.1, Katerina G.1, Pierre Louis R.1, Schwartz E.1  
1IsraAID primary healthcare clinic, Leogane, Haiti, 2Rambam Medical Center, Unit of Infectious Diseases, Haifa, Israel, 3The Center for Geographic Medicine and Tropical Diseases, Sheba Medical Center, Ramat Gan, Israel, 4Shaare Zedek Medical Center, Jerusalem, Israel, 5IsraAID primary healthcare clinic, Leogane, Haiti, 6University of Toronto, Toronto, Canada, 7Tel Hashomer & Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
PO01.17
*Attitudes and practice in malaria prevention in a Public Travel Medicine Clinic in Brazil.*
Froes M.H., Alves J.R., Chaves T.D.S.S.
1Infectious Diseases Institute Emilio Ribas, Travel Clinic Division, Sao Paulo, Brazil

PO01.18
*Dengue in Korea, all imported in relation to international travel*
Lee D.
1Korea Centers for Disease Control and Prevention, Department of Epidemic Intelligence Service, Cheongwongun, Korea, Republic of

PO01.19
*Chikungunya fever in Brazilian travellers returning from Asia: The role of travelers as sentinel population for importation of emerging diseases in Brazil. Report of two cases*
1Infectious Diseases Institute Emilio Ribas and Faculdade De Medicina Da Universidade De Sao Paulo, Travel Medicine Division and Infectious Diseases Division (Ambulatório Dos Viajantes), Sao Paulo, Brazil, 2Central/CIEVS do Centro de Vigilância Epidemiológica da Secretaria de Estado da Saúde de São Paulo, Sao Paulo, Brazil, 3Divisão de Doenças Transmitidas por Vetores e Antropozoonoses do Centro de Vigilância Epidemiológica da Secretaria de Estado da Saúde de São Paulo, Sao Paulo, Brazil, 4Centro de Vigilância Epidemiológica da Secretaria de Estado da Saúde de São Paulo, Sao Paulo, Brazil, 5Faculdade de Medicina da Universidade de Sao Paulo, Infectious Diseases Division, Sao Paulo, Brazil, 6Instituto Evandro Chagas, Seção de Arboviroses e Febres Hemorrágicas, Ananindeua, Brazil, 7Instituto Evandro Chagas, Seção de Arboviroses e Febres Hemorrágicas, Ananindeua, Brazil

PO01.20
*Use of Intradermal (ID) Rabies Pre-exposure Prophylaxis (PrEP) in a Canadian Travel Clinic.*
Zimmer R., Teschke J., Lalonde J.
1Odyssey Travel + Travel Clinic, Calgary, Canada

PO01.21
*Surveillance in pediatric and adult patients with Plasmodium falciparum malaria in the USA: Effectiveness and safety of artemether-lumefantrine*
Cousin M., Schlienger R., Walter V., Marrast A.-C., Pandya K.
1Novartis Pharmaceuticals AG, Basel, Switzerland, 2Novartis Pharmaceuticals Corporation, Global Medical Affairs, East Hanover, United States of America

PO01.22
*Investigation of candidate mutations of Plasmodium falciparum artemisinin resistance by a Brazilian reference setting*
Gama B.E., Almeida-de-Oliveira N.K., Moura-Carvalho L.J., Daniel-Ribeiro C.T., Ferreira-da-Cruz M.D.F.
1Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 2La Jolla Bioengineering Institute, San Diego, United States of America

PO01.23
*Imported Malaria in Portugal in Travelers Returning from Angola*
Cardoso S., Abreu C., Coelho R., Santos L., Sarmento A.
1Hospital S João & School of Medicine - Porto, Infectious diseases department, Porto, Portugal, 2Hospital S João & School of Medicine - Porto, Infectious disease department, Porto, Portugal
PO01.24
Diagnostic and prognostic potential of inflammatory cytokines in adult travelers with imported malaria.
Wroczynska A. 1, Nahorski W.L. 1, Myjak P. 2
1 Medical University of Gdansk, Department of Tropical and Parasitic Diseases, Gdynia, Poland, 2 Medical University of Gdansk, Department of Tropical Parasitology, Gdynia, Poland

Immunizations

PO02.01
Intradermal rabies pre-exposure vaccination experience within an occupational health clinical setting.
Gagnon N. 1, Given J. 1, Roberts W. 1, Sabourin M. 1
1 Health Canada, Emergency Preparedness and Occupational Health Directorate, Ottawa, Canada

PO02.02
Current Trend of Pre-travel Vaccination in Nara Seibu Hospital of Japan
Sakurai M. 1, Sakurai R. 1
1 Nara Seibu Hospital, Nara, Japan

PO02.03
Meningococcal vaccination patterns of travelers from Greece visiting developing countries
Pavli A. 1, Smeti P. 1, Spilioti A. 1, Vakali A. 1, Maltezou H.C. 2
1 Hellenic Centre for Disease Control and Prevention, Travel Medicine Office, Athens, Greece, 2 Hellenic Centre for Disease Control and Prevention, Department for Interventions in Health Care Facilities, Athens, Greece

PO02.04
Modelling the antibody decline following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO®, IC51
Taucher C. 1, Kundi M. 2, Eder S. 1, Dubischar-Kastner K. 1, Schuller E. 1, Klade C. 1
1 Intercell AG, Vienna, Austria, 2 Medical University of Vienna, Institute of Environmental Health, Center for Public Health, Vienna, Austria

PO02.05
Process and outcome accuracy of Hepatitis A and B combined vaccination in travellers: a clinical audit
Masuet Aumatell C. 1, Turner C. 2, Zuckermann J.N. 2
1 Hospital Universitari de Bellvitge, International Health Unit, Preventive Medicine department, l’Hospitalet de Llobregat, Spain, 2 University College London Medical School, WHO Collaborating Centre for Reference, Research and Training in Travel Medicine, Royal Free Travel Health Centre, London, United Kingdom

PO02.06
Rabies pre-exposure prophylaxis for travelers seen in the Boston Area Travel Medicine Network
Hochberg N.S. 1, Barnett E.D. 2, Pfaff M. 3, MacLeod W.B. 3, Iyer H.S. 4, Chen L.H. 5, Wilson M.E. 6, Ooi W.O. 7, Kogelman L. 8, Karchmer A.W. 9, Yanni E. 10, Benoit C.M. 11, Hamer D.H. 3
1 Boston University Schools of Public Health and Medicine, Boston, United States of America, 2 Boston Medical Center, Pediatric Infectious Diseases, Boston, United States of America, 3 Boston University School of Public Health, Center for Global Health and Development, Boston, United States of America, 4 Boston University School of Public Health, Boston, United States of America, 5 Mount Auburn Hospital, Cambridge, United States of America, 6 Centers of Disease Control and Prevention, Atlanta, United States of America, 7 Beth Israel Deaconess Medical Center, Boston, United States of America, 8 Centers for Disease Control and Prevention, Atlanta, United States of America, 9 Tufts Medical Center, Boston, United States of America, 10 Beth Israel Deaconess Medical Center, Boston, United States of America, 11 Boston Medical Center, Boston, United States of America
PO02.07
Characteristics of travelers to countries with endemic typhoid, yellow fever or Japanese encephalitis who were not vaccinated at the pre-travel visit: results from the Boston Area Travel Medicine Network
Hochberg N.S.1,2, Barnett E.D.3, Pfaff M.4, MacLeod W.B.4, Chen L.H.5, Karchmer A.W.6, Wilson M.E.7, Yanni E.8, Benoit C.M.9, Ooi W.W.9, Kogelman L.10, Hamer D.H.4
1Boston University School of Public Health, Department of Epidemiology, Boston, United States of America, 2Boston University School of Medicine, Section of Infectious Diseases, Department of Medicine, Boston, United States of America, 3Boston Medical Center, Section of Pediatric Infectious Diseases, Boston, United States of America, 4Beth Israel Deaconess Medical Center, Division of Infectious Disease, Boston, United States of America, 5Harvard School of Public Health, Department of Global Health and Population, Boston, United States of America, 6Mount Auburn Hospital, Department of Medicine, Boston, United States of America, 7Mount Auburn Hospital, Department of Medicine, Boston, United States of America, 8Beth Israel Deaconess Medical Center, Division of Infectious Disease, Boston, United States of America, 9Lahey Clinic Medical Center, Department of Infectious Disease, Burlington, United States of America, 10Tufts Medical Center, Division of Geographic Medicine and Infectious Diseases, Boston, United States of America

PO02.08
Cross-reactive immune response against Salmonella paratyphi after live oral Ty21a typhoid (Vivotif®) vaccination
Kantele A.1,2, Pakkanen S.2, Kantele J.3
1Helsinki University Central Hospital, Helsinki, Finland, 2University of Helsinki, Helsinki, Finland, 3University of Turku, Turku, Finland

PO02.09
Strengthening country-specific recommendations for pre-travel typhoid vaccination
Johnson K.J.1, Gallagher N.2, Mintz E.D.2, Newton A.E.2, Brunette G.W.1, Kozarsky P.1
1Centers for Disease Control and Prevention, Travelers’ Health, Division of Global Migration and Quarantine, Atlanta, United States of America, 2Centers for Disease Control and Prevention, Division of Foodborne, Waterborne, and Environmental Diseases, Atlanta, United States of America

PO02.10
Analysis of US CDC Web-Based Registry of Yellow Fever Vaccine Clinics and Stamp Owners
Sommers T.1, Gallagher N.1, Han P.1, Miller C.2, Kozarsky P.1, Gershman M.1
1Travelers’ Health Branch, Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, United States of America, 2Strategic Science and Program Unit, Office of Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, United States of America

PO02.11
Surveillance of adverse events following immunization of travelers vaccinated at a travel health clinic, Regina, Saskatchewan, Canada.
Diener T.1, Abbas Z.1, Granger M.1, Martin D.1
1Regina Qu’Appelle Health Region, Population and Public Health, Regina, Canada

PO02.12
Detection of Yellow Fever Immunoglobulin M Antibodies at 3-4 Years Following Yellow Fever Vaccination
Gibney K.B.1,2, Edupuganti S.3, Panella A.J.1, Delorey M.J.1, Weaver B.3, Lanciotti R.S.1, Fischer M.1, Staples J.E.1
1Centers for Disease Control and Prevention, Arboviral Diseases Branch, Fort Collins, United States of America, 2Centers for Disease Control and Prevention, Epidemic Intelligence Service Program, Atlanta, United States of America, 3Emory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, United States of America
PO02.13
Immunogenicity of Two Doses of Investigational HEPLISAV™ (HBsAg-ISS) Compared to Three Doses of Licensed Hepatitis B Vaccine (ENGERIX-B®)
Malhame M.1, Heyward W.1, Martin J.T.1
1Dynavax Technologies, Berkeley, United States of America

PO02.14
Yellow Fever Immunization for the Solid Organ Recipients Travellers
Bourée P.1,2, Bisaro F.3,4
1Paris XI University, Tropical Disaeses Dept, Kremlin-Bicetre, France, 2Institut Fournier, Tropical Disaeses Dept, Paris, France, 3Bicetre Hospital, APHP, Tropical Diseases Dept, Kremlin-Bicetre, France, 4Paris VII University, Life Science Unit, Paris, France

PO02.15
Effectiveness of WC/rBS cholera vaccine in preventing travelers diarrhea
Lopez-Gigosos R.M.1, Campins M.2, Diez J.3, Perez-Hoyos S.3, Calvo M.J.4, Salleras L.5
1International Vaccination Center, Malaga, Spain, 2Hospital Vall d’ Hebron, Barcelona, Spain, 3Centre for Public Health Research, Valencia, Spain, 4International Vaccination Center, Santander, Spain, 5University of Barcelona, Barcelona, Spain

PO02.16
Immunity to Japanese encephalitis and booster vaccine efficacy in Japanese travelers
Takeshita N.1, Mizuno Y.1,2, Lim C.-K.3, Kotaki A.3, Ujiie M.1, Kato Y.1, Kanagawa S.1, Takasaki T.3, Kudo K.1
1National Center for Global Health and Medicine, Travel clinic, Tokyo, Japan, 2Tokyo Medical University Hospital, Tokyo, Japan, 3National Institute of Infectious Diseases, Department of virology 1st, Tokyo, Japan

PO02.17
Low response rate in diabetes patients but not in chronic obstructive pulmonary disease patients after vaccination with hepatitis B vaccine (Engerix B®).
Hoebe C.J.P.A.1,2, ter Waarbeek H.L.G.1,2, Dukers-Muijrers N.H.T.M.1,2
1Public Health Service South Limburg, Infectious Disease Control, Geleen, Netherlands, 2Maastricht University Medical Centre, Medical Microbiology / CAPHRI, Maastricht, Netherlands

PO02.18
A/H1N1sw seroprevalence after swine flu pandemic and pandemic / seasonal vaccinations in Hamburg, Germany, and implications for subsequent influenza season
Cramer J.P.1,2, Mac T.2, Hogan B.1, Stauga S.2, Eberhardt S.3, Wichmann O.3, Mertens T.4, Burchard G.D.1,2
1Bernhard-Nocht-Institute of Tropical Medicine, Clinical Research Group, Hamburg, Germany, 2University Medical Center Hamburg-Eppendorf, Section Tropical Medicine, Hamburg, Germany, 3Robert Koch Institute, Section Infection Epidemiology, Berlin, Germany, 4University Medical Center Ulm, Department of Virology, Ulm, Germany

PO02.19
Acceptance and attitude towards H1N1 influenza vaccination among Health Care Personnel (HCP) - a report from India
Hemalatha J.1, Sureshkumar D.1,2
1Vaccine Shots Travel and Immunization Clinic, Travel Clinic, Chennai, India, 2Apollo Hospitals Hospitals, Chennai, India
PO02.20
**Double-Dose Hepatitis B Vaccine Administration Among Previous Nonresponders**
Zimmer R., Lalonde J., DeMong L.
1Odyssey Travel + Travel Clinic, Calgary, Canada

PO02.22
**A Penny Saved is a Penny Earned, Estimated Cost Avoidance of International Travel Vaccines**
Crumbaugh E., Flowers S.
1Kroger Pharmacy, North Little Rock, United States of America, 2University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, United States of America

PO02.23
**“I’m Leaving Tomorrow” - The Potential Use of Partial Vaccine Series and/or Double Dosing in Adult Travellers Who Present for Late Consultation**
Tepper M., Crane F., Schofield S., Anderson J.
1Department of National Defence, Force Health Protection, Ottawa, Canada

PO02.24
**Yellow Fever Vaccine Seroconversion in Travelers**
Kay A., Chen L.H., Gottlieb K., Sisti M., Monath T.
1Mount Auburn Hospital, Cambridge, United States of America, 2Harvard Medical School, Boston, United States of America, 3Massachusetts College of Pharmacy and Health Sciences, Manchester, United States of America, 4Focus Diagnostics, Cypress, United States of America, 5Sisti Consulting Inc, Sausalito, United States of America, 6Xcellerex Inc, Marlborough, United States of America

PO02.25
**Viscerotropic Disease After Yellow Fever Vaccination. First report from Argentina**
1Sanatorio Otamendi, Buenos Aires, Argentina, 2Stamboulian, Travel Medicine Division, Buenos Aires, Argentina, 3Instituto Nacional de Enfermedades Virales Humanas (INEVH), Pergamino, Argentina, 4Stamboulian, Travel Medicine Division, Director, Buenos Aires, Argentina

PO02.26
**Comparison of the efficacy of intradermal pre-exposure rabies vaccination using Merieux Human Diploid Cell Vaccine & Purified Chick Embryo Rabies Vaccine**
Lau S.
1The Travel Doctor - TMVC, Mebourne Clinic, Melbourne, Australia

Enteric Infections

PO03.01
**Loperamide is beneficial in the treatment of travelers’ diarrhea regardless of severity of clinical presentation**
Ericsson C., DuPont H., Okhuysen P., Jiang Z.-D., de la Cabada J., DuPont M.
1University of Texas Medical School at Houston, Medicine / Infectious Diseases, Houston, United States of America, 2St. Luke’s Episcopal Hospital, Medicine / Infectious Diseases, Houston, United States of America, 3University of Texas School of Public Health, Center for Infectious Diseases, Houston, United States of America, 4Baylor College of Medicine, Medicine / Infectious Diseases, Houston, United States of America
**PO03.02**

*A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers’ diarrhoea*

Tzortzis G.¹, Gibson G.R.²  
¹Clasado UK, Milton Keynes, United Kingdom, ²The University of Reading, Department of Health and Nutritional Sciences, Reading, United Kingdom

**PO03.03**

*No need to prescribe prophylactic or stand-by antibiotics for travelers diarrhea to short-term immunocompetent travelers: a prospective study.*

Belderok S.-M.¹,², Sonder G.J.¹,², Baaten G.G.¹, Schim van der Loeff M.F.¹,², van den Hoek J.A.¹,²  
¹Public Health Service Amsterdam, Infectious Diseases, Amsterdam, Netherlands, ²Academic Medical Centre, Infectious diseases, Tropical Medicine and Aids, Amsterdam, Netherlands

**PO03.04**

*Typhoid fever in returning travelers and immigrants seen at a Bronx municipal hospital, 2005-2010*

Farmakiotis D.¹, Sue P.², Varughese J.³, Andrews P.², Brimmage M.², Dobroszycki J.³, Coyle C.¹  
¹Albert Einstein College of Medicine/Jacobi Medical Center, Medicine, Bronx, United States of America, ²Albert Einstein College of Medicine/Jacobi Medical Center, Pediatrics, Bronx, United States of America, ³Albert Einstein College of Medicine/ Montefiore Medical Center, Infectious Diseases, Bronx, United States of America

**PO03.05**

*A Double-blind, Randomized, Crossover trial of Novel Site-Activated Botanical Metabolites with Oral Rehydration Therapy for Short-Term Diarrhea in Adults*

Dover A.S.¹  
¹APTOS Travel Clinic, Watsonville, United States of America

**PO03.06**

*A Double-blind, Randomized, Crossover trial of Novel Site-Activated Botanical Metabolites with Oral Rehydration Therapy for Short-Term Diarrhea in Children.*

Dover A.S.¹  
¹APTOS Travel Clinic, Watsonville, United States of America

**PO03.07**


Nakadomari T.¹, Silva I.¹, Mazzuco M.¹, Infante V.¹, Siveli R.¹, Chaves T.S.S.¹  
¹Infectious Diseases Institute Emilio Ribas, Travel Medicine Division, Sao Paulo, Brazil

**PO03.08**

*Combination therapy with ceftriaxone and azithromycin for Salmonella paratyphi A bacteremia among Israeli travelers to Nepal*

Meltzer E.¹, Leshem E.¹, Stienlauf S.¹, Ostfeld I.², Weiner- Well Y.³, Megged O.³, Potasman I.⁴, Schwartz E.¹  
¹Sheba Medical Center, The Center for Geographic Medicine and Internal Medicine C, Ramat Gan, Israel, ²Rabin Medical Center, Petah Tikva, Israel, ³Shaare Zedek Medical Center, Jerusalem, Israel, ⁴Bnai Zion Medical Center, Haifa, Israel
PO03.09
Toxin-Producing Non-Escherichia coli Enterobacteriaceae as Potential Causes of Travelers’ Diarrhea
Jiang Z.-D.1, Oben C.1, Dupont H.L.1,2, Nandy R.3, Ramamurthy T.3, Gurleen K.4, Rodrigues S.4, McKenzie R.5, Steffen R.6
1University of Texas Medical School at Houston, Houston, United States of America, 2Baylor College of Medicine, Houston, United States of America, 3National Institute of Cholera and Enteric Diseases, Kolkata, India, Kolkata, India, 4Goa Medical College, Bambolim Goa, India, Goa, India, 5Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, Baltimore, United States of America, 6Institute of Social and Preventive Medicine of the University, Zurich, Switzerland

PO03.10
Evaluation of Available Transport Systems for Identification of Enteric Bacterial Pathogens and an Examination of Optimal Temperature for Transportation
Jiang Z.-D.1, Dupont H.L.1,2, Sistrunk J.1
1University of Texas Medical School at Houston, Houston, United States of America, 2Baylor College of Medicine, Houston, United States of America

PO03.11
Tyhoid fever in the global world
Pereira B.I.1, Seixas D.1, Crespo P.1, Malcata L.1, Serra J.E.1, Oliveira J.1, Saraiva da Cunha J.1
1University Hospital of Coimbra, Portugal, Infectious Diseases Department, Coimbra, Portugal

Special Needs Travelers

PO04.01
Travelers visiting friends and relatives (VFRs) seen in the Boston Area Travel Medicine Network (BATMN): Risks of malaria and yellow fever and intention to use anti-vector measures.
1Boston Medical Center, Pediatric Infectious Diseases, Boston, United States of America, 2Boston University School of Public Health, Center for Global Health and Development, Boston, United States of America, 3Mount Auburn Hospital, Department of Medicine, Cambridge, United States of America, 4Harvard Medical School, Boston, United States of America, 5Harvard University School of Public Health, Department of Global Health and Population, Boston, United States of America, 6Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States of America, 7Tufts Medical Center, Division of Geographic Medicine and Infectious Diseases, Boston, United States of America, 8Beth Israel Deaconess Medical Center, Division of Infectious Disease, Boston, United States of America, 9Lahey Clinic Medical Center, Department of Infectious Disease, Burlington, United States of America

PO04.02
Health Status and Challenges of Youth Travelers Aged ≤ 21 Years: Comparison of Those Visiting Friends and Relatives with those Traveling for Other Purposes
Han P.1, Yanni E.1, Jentes E.S.1, Hamer D.H.2, MacLeod W.B.2, Pfaff M.2, Karchmer A.W.3, Kogelman L.4, Ooi W.W.5, Chen L.H.6, Wilson M.E.7, Barnett E.D.8
1Centers for Disease Control and Prevention, Atlanta, United States of America, 2Boston University School of Public Health, Boston, United States of America, 3Beth Israel Deaconess Medical Center, Boston, United States of America, 4Tufts Medical Center, Boston, United States of America, 5Lahey Clinic Medical Center, Burlington, United States of America, 6Mount Auburn Hospital, Cambridge, United States of America, 7Harvard School of Public Health, Boston, United States of America, 8Boston Medical Center, Boston, United States of America
PO04.03
Menstrual cycle abnormalities amongst South African female Hajj pilgrims during 2008 and 2009
Parker S.¹, Omar S.²
¹SASTM (South African Society of Travel Medicine), Johannesburg, South Africa, ²University of Witwatersrand, Intensive Care Unit, Johannesburg, South Africa

PO04.04
Analysis of returned humanitarian aid and mission workers seen at InterHealth, UK
Boddington N.L.¹
¹InterHealth, London, United Kingdom

PO04.05
Yellow Fever Vaccine Given to Travelers Living With Autoimmune Disorders
Zimmer R.¹, Lalonde J.¹, Fonseca K.²
¹Odyssey Travel + Travel Clinic, Calgary, Canada, ²Provincial Laboratory for Public Health, Calgary, Canada

PO04.06
Pre-travel preparation and travel-related morbidity in patients with inflammatory bowel disease
Soonawala D.¹, van Eggermond A.M.¹, Fidder H.², Visser L.G.¹
¹Leiden University Medical Center, Department of Infectious and Tropical Diseases, Leiden, Netherlands, ²University Medical Center Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands

PO04.07
Causes of Medical Attention among Travelers with Pre-existing Health Conditions Visiting Havana
Izquierdo Albert F.A.¹
¹Cira Garcia Central Clinic, Internal Medicine, Havana, Cuba

PO04.08
Contact Lens Safety and Eye Health in Travelers - Risks and Recommendations
Behlau I.¹,², Ozcelik S.D.³, Avery K.A.³, Wilson M.E.¹,², Dohlman C.H.², Pineda II R.²
¹Mount Auburn Hospital, Infectious Diseases and Travel Medicine, Cambridge, United States of America, ²Massachusetts Eye and Ear Infirmary, Ophthalmology, Boston, United States of America, ³Schepens Eye Research Institute, Boston, United States of America, ⁴University of Pennsylvania, Philadelphia, United States of America, ⁵Mount Auburn Hospital, Travel Medicine, Cambridge, United States of America, ⁶Harvard School of Public Health, Boston, United States of America

Migrants and Refugees

PO05.01
Analysis of Clinical Contents of Foreign Outpatients in University Hospital
Yoo B.¹
¹Soonchunhyang University Hospital, Family Medicine, Seoul, Korea, Republic of

PO05.02
Socio-demographic Characteristics of the Immigrants Entering Hatay Province of Turkey Through Illegal Ways
Aytac N.¹, Nazlican E.¹, Kara E.¹, Akbaba M.¹
¹Cukurova University Faculty of Medicine, Public Health, Adana, Turkey
PO05.03
Level of Knowledge About Breast Cancer of Immigrant Women in Fertile Years Old
Aytac N.1, Gunduz E.1, Kara E.1, Akbaba M.1
1Çukurova University Faculty of Medicine, Public Health, Adana, Turkey

PO05.04
Imported Infectious Disease by Immigrants in Spain: Results from the Spanish Network on Imported Infectious Diseases by travellers and Immigrants (+Redivi).
1Hospital Universitario Ramón y Cajal, Madrid, Spain, 2CAP Drassanes, Barcelona, Spain, 3Hospital General Universitario de Alicante, Alicante, Spain, 4Hospital 12 de Octubre, Madrid, Spain, 5Hospital Universitario de Guadalajara, Guadalajara, Spain, 6CAP Caramuel, Madrid, Spain, 7Hospital Universitario La Paz, Madrid, Spain, 8Hospital Infanta Sofía, Madrid, Spain, 9Complexo Hospitalario Universitario A Coruña, A Coruña, Spain

PO05.05
Strongyloides in migrant population in NY
Piper Jenks N.1, Vogel A.1
1Hudson River Community Health, Peekskill, United States of America

PO05.06
Vivax Malaria Outbreak in Eritrean Refugees, Israel, 2010
Kopel E.1, Schwartz E.2, Goldmann D.3, Amitai Z.1, Sheffer R.1, Anis E.3
1Ministry of Health, Tel Aviv District Health Office, Tel Aviv, Israel, 2Sheba Medical Center, Center for Geographic Medicine and Tropical Diseases, Ramat Gan, Israel, 3Ministry of Health, Division of Epidemiology, Jerusalem, Israel

PO05.07
Screening for Trypanosoma cruzi and other transmissible infections in a cohort of pregnant Latin American women, Madrid, Spain
Norman F.F.1, Monge-Maillo B.1, Abarca-Martínez L.2, Pablos-Antona M.J.2, Pelayo-Delgado I.2, Pérez-Molina J.A.1, Pérez-Ayala A.1, Díaz-Menéndez M.1, delJosé-Gomez M.I.3, López-Vélez R.1
1Ramón y Cajal Hospital, Tropical Medicine-Infectious Diseases, Madrid, Spain, 2Ramón y Cajal Hospital, Gynecology Department, Madrid, Spain, 3La Paz Hospital, Pediatrics Department, Madrid, Spain

PO05.08
Primary health-care center in post-earthquake Haiti: preliminary data
Neuberger A.1,2, tenenboim S.1, Oshri Z.1, Racheli P.1, Urman M.1,4, Karen H.1,5, Spencer V.1, Katerina G.1, Eli S.1,3,6
1IsraAID primary healthcare clinic, Leogane, Haiti, 2Rambam Medical Center, Unit of Infectious Diseases, Haifa, Israel, 3The Center for Geographic Medicine and Tropical Diseases, Sheba Medical Center, Ramat Gan, Israel, 4Shaare Zedek Medical Center, Jerusalem, Israel, 5University of Toronto, Department of Family and Community Medicine, Toronto, Canada, 6Tel Hashomer & Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

PO05.09
Parasitic diseases imported by immigrants in a tropical diseases reference hospital: 4636 cases.
Puente S.1, Ramírez-Olivencia G.1, Lago M.M.1, Herrero M.D.1, Rivas P.1, Subirats M.2
1Hospital Carlos III, Tropical Medicine. Infectious Diseases, Madrid, Spain, 2Hospital Carlos III, Service of Microbiology, Madrid, Spain
PO06.01

Tuberculosis conversion in New Zealand Police personnel deploying overseas: A retrospective review.

Visser J.T.¹, Campbell B.², Narayanan A.³

¹Wellington School of Medicine & Health Sciences University of Otago, General Practice & Primary Health Care, Wellington, New Zealand, ²The Travel Doctor, Wellington, New Zealand, ³University of Otago, Wellington, New Zealand

PO06.02

Strongyloidiasis Incidence (New Zealand Police International Services Group) - A Three Year Retrospective Review

Campbell B.K.¹, Visser J.T.², Narayanan A.³

¹The Travel Doctor, Wellington, New Zealand, ²Wellington School of Medicine & Health Sciences University of Otago, General Practice and Primary Health Care, Wellington, New Zealand, ³University of Otago, Dunedin, New Zealand

PO06.03

Clinical features of imported cases of dengue fever in Japan

Mizuno Y.¹, Kato Y.², Takeshita N.², Ujiie M.², Kanagawa S.², Kotaki A.³, Moi M.L.³, Takasaki T.³

¹Tokyo Medical University Hospital, Travellers’ Medical Center, Department of Infection Control and Prevention, Tokyo, Japan, ²National Center for Global Health and Medicine, Disease Control and Prevention Center, Tokyo, Japan, ³National Institute of Infectious Diseases, Department of Virology 1, Tokyo, Japan

PO06.04

Imported Malaria in Auckland, New Zealand

Elinder A.¹, Ingram R.J.H.²

¹ADHB, Auckland, New Zealand, ²ADHB, Infectious Diseases, Auckland, New Zealand

PO06.05

Diagnosis of travel-related Schistosoma haematobium acquired in the Dogon Valley in Mali

Soentjens P.H.P.¹,², Aerssens A.¹, Yansouni C.P.², Clerinx J.², Van Gompel A.²

¹Center for Infectious Diseases, Brussels, Belgium, ²Institute of Tropical Medicine, Clinical Sciences, Antwerp, Belgium

PO06.06

Skin disorders among international travelers: a retrospective analysis of 4,158 cases

Siess C.¹, Nothdurft H.D.¹, von Sonnenburg F.¹, Löscher T.¹, Herbinger K.-H.¹

¹University of Munich, Tropical Medicine and Infectious Diseases, Munich, Germany

PO06.07

Travel related health problems - A 6 years study in Tokyo -

Yamauchi Y.¹, Ujiie M.¹, Takeshita N.¹, Kato Y.¹, Kanagawa S.¹, Kudo K.¹

¹National Center for Global Health and Medicine, Tokyo, Japan

PO06.08

Fever in returning travelers: a systematic review of incubation periods for the main imported tropical diseases

Rossi I.A.¹, Genton B.¹,²,³, D’acremont V.¹,³

¹Travel Clinic, Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland, ²Division of Infectious Diseases, University Hospital, Lausanne, Switzerland, ³Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland
PO06.09
Travel-related Hepatitis A infection in a Previous Non-responder to the Vaccine
Zimmer R.1
1Odyssey Travel + Travel Clinic, Calgary, Canada

PO06.10
An Outbreak of Schistosomiasis in an Irish School
Kiely B.1, Fry G.1
1Tropical Medical Bureau, Dublin, Ireland

PO06.11
Clinical and Epidemiological Characteristics of the Fever from the Tropics Cases Hospitalised in a Specialized Unit in a University Hospital.
Pini A.1, Gulletta M.1, Tomasoni L.R.1, De Nardi S.1, Urbinati L.1, Rodari P.1, Castelli F.1
1Istituto di Malattie Infettive e Medicina Tropicale di Brescia, Italy, Brescia, Italy

PO06.12
Clostridium difficile in returning travelers
Suri J.1, Anand R.1, Sofarelli T.1, Hale D.1
1University of Utah, School of Medicine, Division of Infectious Diseases, Salt Lake City, United States of America

PO06.13
Parasitic Imported Diseases in a tropical diseases reference hospital: 9,303 travelers attended.
Puente S.1, Subirats M.2, Rivas P.1, Lago M.M.1, Herrero M.D.1, Ramírez-Olivencia G.1
1Hospital Carlos III, Tropical Medicine. Infectious Diseases., Madrid, Spain, 2Hospital Carlos III, Service of Microbiology, Madrid, Spain

PO06.14
Health Problems of Spiritual/Heritage Tourists and Christian “Hajji” Pilgrims Upon Returning from the Middle East
Vassalos C.M.1, Vassalou E.1, Sofos N.2, Vakalis N.3
1National School of Public Health, Travel Medicine Unit/Department of Tropical Diseases, Athens, Greece, 2Prefectural District of South Athens, Health Department, Athens, Greece, 3National School of Public Health, Department of Tropical Diseases, Athens, Greece
PO06.15
Travel-related imported infections in Europe, EuroTravNet 2009
Odolini S.1, Parola P.2, Gkrania-Klotsas E.3, Caumes E.4, Schlägenhauf P.5, López-Vélez R.6, Burchard G.-D.7, Santos-O’Connor F.8, Weld L.9, von Sonnenburg F.10, Field V.11, De Vries P.12, Jensenius M.13, Loutan L.14, Castelli F.1
1Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, 2Service des Maladies Infectieuses et Tropicales, Hôpital Nord, AP-HM, Marseille, France, 3Addenbrooke’s Hospital, Hills Road, Infectious Diseases Department, Cambridge University Hospital, Cambridge, United Kingdom, 4Service des Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, Paris, France, 5University of Zurich Center for Travel Medicine, University of Zurich, Hirschengraben, Zurich, Switzerland, 6Tropical Medicine and Clinical Parasitology. Infectious Diseases Dept., Ramon y Cajal Hospital, Madrid, Spain, 7University Medical Center Hamburg-Eppendorf, Dept. of Tropical Medicine and Bernhard-Nocht Outpatient Dept., Hamburg, Germany, 8European Centre for Disease Prevention and Control, Stockholm, Sweden, 9ISTM/Geosentinel Statistician Consultant, Victoria B.C., Canada, 10Dept. of Infectious Diseases and Tropical Medicine, LMU University of Munich, Munich, Germany, 11InterHealth and National Travel Health Network and Center (NaTHNaC), London, United Kingdom, 12Division of Infectious, Tropical Medicine and AIDS, Academic Medical Centre, Amsterdam, Netherlands, 13Oslo University Hospital Ullevål and University of Oslo, Oslo, Norway, 14Division of International and Humanitarian Health, Geneva University Hospitals, Geneva, Switzerland

PO06.16
New England souvenirs
Vugt van M.1, Wetsteyn J.1, Hillebrand M.1, Kolader M.2, Verhaar N.2, Spanjaard L.2, Grobusch M.P.1, Bart A.2, Gool van T.2
1Academic Medical Center, Amsterdam, Division of Internal Medicine-ITA, Amsterdam, Netherlands, 2Academic Medical Center, Amsterdam, Division of Internal Medicine-ITA- Medical Microbiology, Amsterdam, Netherlands

PO06.17
Tuberculin Skin Test Conversion Rate among Short Term Health Care Workers Returning from Gaborone, Botswana
Szep Z.1, Kim R.2, Ratcliffe S.J.3, Gluckman S.1
1University of Pennsylvania School of Medicine, Department of Medicine, Philadelphia, United States of America, 2Cooper University Hospital, Department of Medicine, Camden, United States of America, 3University of Pennsylvania School of Medicine, Department of Biostatistics and Epidemiology, Philadelphia, United States of America

PO06.18
Imported cutaneous leishmaniasis in travellers (1981-2009) Experience in Argentina
Orduna T.A.1, Lloveras S.C.1, González G.1, Falcone C.1, Garro S.S.1, Echazarreta S.E.1
1Hospital F. J. Muñiz, Tropical Medicine-Travel Medicine, Buenos Aires, Argentina

PO06.19
Cutaneous leishmaniasis in local and international travelers in Peru
Siu H.R.1, Valencia B.1, Llanos A.1, Institute of Tropical Medicine Alexander von Humboldt (IMTAvH)
1Universidad Peruana Cayetano Heredia, Medicine, Lima, Peru
Infectious Diseases – Epidemiology, Diagnosis, Treatment

PO07.01
Cerebral Spinal Fluid (CSF) lactate (using a hand-held monitor) as a tool in the diagnosis of meningitis in patients admitted with clinical suspicion of meningitis on the medical ward in Mbarara Regional Referral Hospital.
Majwala A.1, Moore C.C.2, Muzoora C.1, Wilson T.1
1Mbarara University of Science and Technology, Internal Medicine, Mbarara, Uganda, 2University of Virginia, Infectious Disease and International Health, Charlottesville, United States of America

PO07.02
An epidemiological study of cutaneous leishmaniasis in the province of Osmaniye, Turkey, between 2008 and 2009
Kara E.1, Akbaba M.1, Aytac N.1
1Cukurova University Faculty of Medicine, Public Health, ADANA, Turkey

PO07.03
Evaluation of measures used to prevent respiratory illness among US Travelers to the 2009 Hajj in Mecca
Balaban V.1, Stauffer W.2, Hammad A.3, Afgarshe M.4, Abd Alla M.5, Ahmed Q.6, Memish Z.7, Saba J.3, Harton E.8, Palumbo G.8, Marano N.1
1Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States of America, 2University of Minnesota, Division of Infectious Disease and International Medicine, Minneapolis, United States of America, 3Arab Community Center for Economic & Social Services, Dearborn, United States of America, 4HealthPartners, Minneapolis, United States of America, 5Medical College of Wisconsin, Division of Infectious Diseases, Milwaukee, United States of America, 6Winthrop University, Division of Pulmonary, Sleep and Critical Care Medicine, Mineola, United States of America, 7Ministry of Health, Kingdom of Saudi Arabia, Riyadh, Saudi Arabia, 8Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Detroit, United States of America

PO07.04
The Incidence of Upper Respiratory Tract Infections and Influenza-like illness amongst South African Hajj Pilgrims in 2010
Parker S.1, Mendelson M.2
1SASTM (South African Society of Travel Medicine), Johannesburg, South Africa, 2University of Cape Town, Medicine, Cape Town, South Africa

PO07.05
Hand hygiene - gaps in knowledge and practice among medical students of a developing country, Pakistan.
Rehman A.1, mahmood S.F.2, asif A.1, Tahir F.3
1Dow medical College, Internal Medicine, Karachi, Pakistan, 2Aga Khan University, MD, FACP, Dept of Internal Medicine, Infectious Disease section, Karachi, Pakistan, 3Dow medical College, Karachi, Pakistan

PO07.06
Parasitic infections among Romanian institutionalized children and their medical staff
Olariu T.R.1, Dumitrescu V.1, Darabus G.2, Mederle O.1, Petrescu C.1, Koreck A.1
1Victor Babes University of Medicine and Pharmacy, Timisoara, Romania, 2Faculty of Veterinary Medicine, Timisoara, Romania
PO07.07
Trends in antimalarial prescriptions in Australia 2005-2008
Leggat P.A.1,2
1James Cook University, Anton Breinl Centre, Townsville, Australia, 2University of the Witwatersrand, School of Public Health, Johannesburg, South Africa

PO07.08
Leishmaniasis due to Leishmania aethiopica treated with liposomal amphotericin B in a traveler returning from Eritrea
Zanger P.1, Gelanew T.2,3, Kötter I.4, Raible A.4, Schönian G.5, Kremsner P.G.1
1Eberhard Karls Universität, Institut für Tropenmedizin, Tübingen, Germany, 2Charité Universitätsmedizin Berlin, Institut für Mikrobiologie und Hygiene, Berlin, Germany, 3Adis Abbaba University, Faculty of Medicine, Addis Abbaba, Ethiopia, 4Eberhard Karls Universität, Medizinische Klinik, Tübingen, Germany

PO07.09
Clinical syndrome, stage, and therapy in a cohort of travel-related Schistosoma haematobium acquired in the Dogon Valley in Mali.
Soentjens P.H.P.1,2, Aerssens A.1,2, Yansouni C.2, Clerinx J.2, Van Gompel A.2
1Center for Infectious Diseases, Brussels, Belgium, 2Institute of Tropical Medicine, Clinical Sciences, Antwerp, Belgium

PO07.10
Melioidosis an Emerging Infectious Disease in India
Hemalatha J.1, Sureshkumar D.1,2, Ramgopalakrishnan R.2, Ramasubramanian V.2, Abdulghafur K.2
1Vaccine Shots Travel and Immunization Clinic, Travel Clinic, Chennai, India, 2Apollo Hospitals, Infectious Diseases, Chennai, India

PO07.11
Origins of Travel Medicine in an Exhibition on Old and New Epidemics
Pasini W.1
1Centre for Travel Medicine and Global Health, Rimini, Italy

PO07.12
Imported rickettsiosis from sub-Saharan Africa: 115 cases
Puente S.1, Ramirez-Olivencia G.1, Herrero M.D.1, Subirats M.2, Rivas P.1, Lago M.M.1
1Hospital Carlos III, Tropical Medicine. Infectious Diseases, Madrid, Spain, 2Hospital Carlos III, Service of Microbiology, Madrid, Spain

PO07.13
Disparities Exist in the Availability of Antimalarial Medication in the United States of America
Hickey P.W.1,2, Lamson M.1, Hall M.T.1, Thomas N.2, Coldren R.L.1
1Uniformed Services University, Preventive Medicine, Bethesda, United States of America, 2Uniformed Services University, Pediatrics, Bethesda, United States of America

PO07.15
Border Control Measures and Territorial Surveillance in American Samoa for the 2009 H1N1 Influenza Pandemic
Bouslough D.B.1, Turituri F.1, Mageo S.1, Lemusu S.1
1LBJ Tropical Medical Center, Pago Pago, American Samoa
PO07.16
Experience from a new Travel Clinic in Lisbon, 2008-10
Lino S.1, Alves A.1, Gomes R.1, Casimiro J.1, Loureno C.1, Neves Z.1, Catarino M.1, Rodrigues P.1, Cardoso O.1, Garrido N.1, Martins T.1, Manata M.1, Correia F.1, Machado J.1, Maltez F.1
1Hospital Curry Cabral, Infectious Diseases, Lisbon, Portugal

Impact on Host Country

PO08.01
Designing an Assessment Tool for Tourism’s Health Impacts in Developing Countries. Step 2: Asking the Right Question - An Example from Peru
Bauer I.L.1,2
1James Cook University, Nursing, Midwifery & Nutrition, Townsville, Australia, 2Curtin University of Technology, Centre for International Health, Perth, Australia

PO08.02
Prevalence of respiratory viruses in ecotourists: Towards an understanding of risks of anthrozoonoses at wildlife tourism destinations
Muehlenbein M.P.1, Prall S.P.1
1Indiana University, Anthropology, Bloomington, United States of America

PO08.03
Cross-border health in the European Union
Guillermo Ramirez M.1
1Association of European Border Regions, Gronau, Germany

Long-Stay Travelers

PO09.01
Diseases among Japanese Children staying abroad
Fukushima S.1, Hamada A.2
1Tokyo Medical University Hospital, Travellers’ Medical Center, Shinjuku, Japan, 2Tokyo Medical University Hospital, Shinjuku, Japan

PO09.02
Health Issues in International Travelers on Extended Stay in Africa
Hughes R.D.1, Nworfor-Jones C.1, Agoru O.1, Slocum R.1, Easterling K.T.1
1Jamaica Hospital Medical Center, Department of Family Medicine, Jamaica, United States of America

PO09.03
Mantoux tuberculin skin test may be read in a travel clinic up to 7 days after administration of PPD
Lau S.1
1The Travel Doctor - TMVC, Mebourne Clinic, Melbourne, Australia
PO10.01
Pediatric International Travelers and Travel Health Preparations: Analysis from the U.S. Global TravEpiNet Consortium
Hagmann S.1,2, LaRocque R.C.3,4, Rao S.R.5, Jentes E.S.6, Ryan E.T.3,4, Global TravEpiNet Consortium
1Bronx-Lebanon Hospital Center, Division of Pediatric Infectious Diseases, Bronx, United States of America, 2Albert-Einstein College of Medicine, Department of Pediatrics, Bronx, United States of America, 3Massachusetts General Hospital, Division of Infectious Diseases, Boston, United States of America, 4Harvard Medical School, Department of Medicine, Boston, United States of America, 5Massachusetts General Hospital, Biostatistics Center, Boston, United States of America, 6Center for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States of America

PO10.02
Demographics, Destinations, and Yellow Fever Vaccine Usage Among US Travelers Visiting Countries with Risk of Yellow Fever Virus Transmission
Jentes E.S.1, Han P.1, Rao S.R.2, Larocque R.3,4, Kozarsky P.1, Ryan E.T.3,4, the Global TravEpiNet Consortium
1Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States of America, 2Massachusetts General Hospital, Biostatistics Center, Boston, United States of America, 3Massachusetts General Hospital, Division of Infectious Diseases, Boston, United States of America, 4Harvard Medical School, Department of Medicine, Boston, United States of America

PO10.03
Travel medicine in Bosnia and Herzegovina - first steps
Obradovic Z.1
1Institut for Public Health, Canton Sarajevo, Faculty for health Studies, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

PO10.04
Characteristics of travelers to Brazil compared with those visiting other Latin American destinations: results from the Boston Area Travel Medicine Network (BATMN)
1Mount Auburn Hospital, Travel Medicine Center, Cambridge, United States of America, 2Harvard Medical School, Boston, United States of America, 3Harvard School of Public Health, Boston, United States of America, 4Boston University School of Public Health, Boston, United States of America, 5Cambridge Health Alliance, Medicine, Cambridge, United States of America, 6Beth Israel Deaconess Medical Center, Boston, United States of America, 7Lahey Clinic Medical Center, Burlington, United States of America, 8Tufts Medical Center, Boston, United States of America, 9Centers for Disease Control and Prevention, Atlanta, United States of America, 10Boston University School of Public Health, Center for Global Health and Development, Boston, United States of America, 11Boston Medical Center, Boston, United States of America

PO10.05
Comparison of travel clinic patients according to destination, in Kurume university hospital, Japan
Hidaka H.1, Watanabe H.1, Gotoh K.2
1Kurume University School of Medicine, Division of Infectious Diseases, Department of Infectious Medicine, Fukuoka, Japan, 2Kurume University School of Medicine, Department of Pediatrics, Fukuoka, Japan
PO10.06  
Compliance with Vaccinations and Chemoprophylaxis in Slovenian Travelers to South East Asia Countries  
Simonovic Z.1, Turk K.1, Kovacevic M.1, Jordan Markocic O.2, Trop Skaza A.3, Kopilovic B.4  
1Institute of public health Maribor, Maribor, Slovenia, 2Institute of public health Ljubljana, Ljubljana, Slovenia, 3Institute of public health Celje, Celje, Slovenia, 4Institute of public health Koper, Koper, Slovenia

PO10.07  
Effectiveness of Pre-travel Consultation in the Primary Care Setting  
Abd-Elfattah N.1, Ake J.1, Liaw W.1, Bazemore A.1, Travelers  
1VCU - Fairfax Family Practice, Family Medicine, Fairfax, United States of America

PO10.08  
Influenza prevention among travellers: beliefs and perceptions. A cross-sectional study  
Masuet Aumatell C.1, Toovey S.2, Zuckermann J.N.2  
1Hospital Universitari de Bellvitge, International Health Unit, Preventive Medicine department, l’Hospitalet de Llobregat, Spain, 2University College London Medical School, WHO Collaborating Centre for Reference, Research and Training in Travel Medicine, Royal Free Travel Health Centre, London, United Kingdom

PO10.09  
Accuracy of Rabies Post-exposure prophylaxis according two different classifications: a retrospective cohort study in British travellers  
Masuet Aumatell C.1, Turner C.2, Zuckermann J.N.2  
1Hospital Universitari de Bellvitge, International Health Unit, Preventive Medicine department, l’Hospitalet de Llobregat, Spain, 2University College London Medical School, WHO Collaborating Centre for Reference, Research and Training in Travel Medicine, Royal Free Travel Health Centre, London, United Kingdom

PO10.10  
A review of the current role of pharmacists in the provision of travel health services in Australia  
Heslop I.M.1, Bellingan M.1, Speare R.2, Glass B.D.1  
1James Cook University, School of Pharmacy & Molecular Sciences, Townsville, Australia, 2James Cook University, School of Public Health, Tropical Medicine & Rehabilitation Sciences, Townsville, Australia

PO10.11  
Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational study  
1Academic Medical Centre, Amsterdam, Netherlands, 2University for Health Sciences, Medical Informatics and Technology, Hall in Tyrol, Austria, 3Service des Maladies Infectieuses et Tropicales, Hôpital Nord, AP-HM, Marseille, France, 4Ospedale Amedeo di Savoia, Torino, Italy, 5Clinica di Malattie Infettive e Tropicali, Università di Brescia, Brescia, Italy, 6University Hospital Freiburg, Freiburg, Germany, 7Leopold Institut für Tropische Genesekunde, Antwerp, Belgium, 8Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany, 9Berlin Centre for Travel and Tropical Medicine, Berlin, Germany, 10Hochschule Bonn-Rhein-Sieg, Bonn, Germany, 11Clinic of Infectious Disease, University of Udine, Udine, Italy, 12Infection & Tropical Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom, 13Center for Infectious Diseases and Travel Medicine, University Hospital, Freiburg, Germany, 14Medizinische Klinik mit Schwerpunkt Infektiologie, Charite/Campus Virchow-Klinikum, Berlin, Germany, 15SOD Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy, 16Ernst von Bergmann Lungenzentrum, Brandenburg, Germany, 17Consultation de médecine tropicale, Hôpital Avicenne, Bobigny, France
PO10.12

Gender Differences in Portuguese Travelers in the Pre-travel Medical Encounter
Abreu C., Coelho R., Cardoso S., Gomes A., Andrade P., Caldas C., Sarmento A.
1Hospital S João & School of Medicine - Porto, Infectious Diseases Service, Porto, Portugal, 2Hospital S João & School of Medicine - Porto, Internal Medicine Service, Porto, Portugal, 3Hospital S João & School of Medicine - Porto, Director of Infectious Diseases Department, Porto, Portugal

PO10.13

Infants, Altitude and Air Travel
Neumann K.
1Clinical Associate Professor of Pediatrics, New York Presbyterian Hospital–Cornell Medical Center, New York, New Yor, Pediatrics, Forest Hills, United States of America

PO10.14

Development of an online tool to aid clinical decision-making in malaria prevention
Willcox A., Chera H., Pabla J., Ihsan M., Guraewal R.
1A Talent 4 Health Ltd., Cheltenham, United Kingdom, 2Health Team Ltd., Solihull, United Kingdom

PO10.15

Standards of Yellow Fever Vaccination and Travel Medicine Practice in the Republic of Ireland
Flaherty G., Hamza M., Noone P.
1National University of Ireland, Galway, School of Medicine, Galway, Ireland, 2Faculty of Travel Medicine, Royal College of Physicians and Surgeons (Glasgow), Glasgow, United Kingdom, 3Travel Medicine Society of Ireland, Dublin, Ireland, 4Health Service Executive Dublin North-East, Regional Occupational Health Service, Dublin, Ireland

PO10.16

Mefloquine Failure for Malaria Prophylaxis Due to Suboptimal Dose in an “Oversize” Traveler?
Rossanese A., Gobbi F., Angheben A., Marocco S., Monteiro G.B., Bisoffi Z.
1’Sacro Cuore-Don Calabria’ Hospital, Centre for Tropical Diseases, Negrar - Verona, Italy

PO10.17

Mefloquine-Triggered Epilepsy in a Traveler
Rossanese A., Gobbi F., Angheben A., Marocco S., Monteiro G.B., Bisoffi Z.
1’Sacro Cuore-Don Calabria’ Hospital, Centre for Tropical Diseases, Negrar - Verona, Italy

PO10.18

Pre-travel assessment in travelers to the 2010 South Africa Football World Cup
Macchi A.M., Elmassian P., Gallego V.M., Verdaguer V., Della Latta M.P., Stamboulian D.
1Stamboulian, Travel Medicine Division, Buenos Aires, Argentina, 2Stamboulian, Buenos Aires, Argentina, 3Stamboulian, Travel Medicine Division, Director, Buenos Aires, Argentina

PO10.19

Challenges of practicing Travel Medicine in a resource constrained country, Zimbabwe.
Moyo D.D.
1Bulawayo Occupational and Travel health Centre, Bulawayo, Zimbabwe
PO10.20
Managing attitudes of fever from tropics in the areas of health district of brescia, italy
Pini A.1, Tomasoni L.R.1, Caligaris S.1, De Nardi S.1, Odolini S.1, Giorgetti P.1, Arrighini A.2, Castelli F.1
1Istituto di Malattie Infettive e Medicina Tropicale di Brescia, Italy, Brescia, Italy, 2Spedali Civili di Brescia, Italy, Brescia, Italy

PO10.21
The Development and Validation of a Patient Satisfaction Scale for Travel Clinic Services
de Wet D.R.1, Tomasi A.1, Mazzoli Marradi F.2, Giulfrida S.3, Nicosia V.4
1ASL 2 Lucca, Lucca, Italy, Department of Prevention, Pisa, Italy, 2ASL 3 Pistoia, Pistoia, Italy, Department of Prevention, Pistoia, Italy, 3ASP Reggio Calabria, Dipartment of Prevention, Reggio Calabria, Italy, 4Italian Society of Travel Medicine (SIMVIM), Milan, Italy

PO10.22
The Impact of an Electronic Medical Record on the practice of International Travel Medicine at a Large Academic Health System
Mawhorter S.1, Ivansek N.1
1Cleveland Clinic, Infectious Disease, Cleveland, United States of America

PO10.23
Canadian trends of international travel and risk of malaria exposure
Geduld J.1, Bryson M.1, Straight-Caron T.1
1Public Health Agency of Canada, Infectious Disease Prevention and Control Branch, Ottawa, Canada

PO10.24
Using Geospatial Techniques To Identify Target Populations of U.S. Foreign-Born Travelers
Lee Ç.V.1, Gallagher N.1
1CDC, DGMQ, Atlanta, United States of America

PO10.25
Pre travel advice: evaluation of 661 travellers assisted in a public travel medicine unit during 2009 in Buenos Aires, Argentina.
Lloveras S.C.1, Orduna T.A.1, González G.1, Falcone C.1, Garro S.L.1, Echazarreta S.E.1
1Hospital de Infecciosas F. J. Muñiz, Medicina Tropical - Medicina del Viajero (CEMPRA-MT), Buenos Aires, Argentina

PO10.26
Travel Medicine in an Emergency in Public Health: Traveler’S Clinic Experience as Rapid Response in Pre-Travel Medical Advice for Travelers to Haiti
Chaves T.S.S.1, Miyaji K.T.1, Lara A.N.2, Luiz A.M.2, Sartori A.M.2, Lopes M.H.2, Boulos M.2
1Faculdade de Medicina da Universidade de Sao Paulo, Divisão de Moléstias Infecciosas, Sao Paulo, Brazil, 2Faculdade de Medicina da Universidade de Sao Paulo, Divisão de Moléstias Infecciosas e Parasitárias, Sao Paulo, Brazil

PO10.27
Implementation of Prescription Services using Medical Protocols in a Nurse-based Travel Clinic
Jeffery C.1, Zimmer R.1
1Calgary International Travel Clinic, Calgary, Canada
Abstracts Poster Presentations

PO10.28
Is travelling or working in a touristic town a risk factor for Ischaemic Heart Disease?
Mera V.1, Cebrián L.2
1Clinica Benidorm, Internal Medicine, Benidorm, Spain, 2Clinica Britannia, General Medicine, Calpe, Spain

Travel Advice-Approaches and Outcomes

PO11.01
OMAR: A Dutch approach to practical guidelines for repatriation of hospitalized or recently discharged patients.
Frankenmolen A.T.1
1Eurocross Assistance, Medical, Noordwijk, Netherlands

PO11.03
Knowledge of Transmission, Prevention, and Treatment of Dengue Virus Infection in Travelers in the Boston Area Travel Medicine Network (BATMN)
Iyer H.S.1, Barnett E.D.2,3, Benoit C.2, Pfaff M.1, Karchmer A.W.4,5, Kogelman L.6, Chen L.H.7, Jentes E.S.8, Wilson M.E.9,10,11
1Boston University School of Public Health, Center for Global Health and Development, Boston, United States of America, 2Boston Medical Center, Section of Pediatric Infectious Diseases, Boston, United States of America, 3Boston University School of Medicine, Department of Pediatrics, Boston, United States of America, 4Beth Israel Deaconess Medical Center, Division of Infectious Disease, Boston, United States of America, 5Harvard Medical School, Department of Medicine, Boston, United States of America, 6Tufts Medical Center, Division of Geographic Medicine and Infectious Diseases, Boston, United States of America, 7Mt. Auburn Hospital, Department of Medicine, Cambridge, United States of America, 8Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States of America, 9Harvard School of Public Health, Department of Global Health and Population, Boston, United States of America, 10Boston University School of Public Health, Department of International Health, Boston, United States of America, 11Boston Medical Center, Section of Infectious Diseases, Boston, United States of America

PO11.04
Compliance with Malaria preventive measures in international travelers
Rosales M.1, Cambra A.2, Fernandez A.2, Martinez B.2, Martinez E.2, Jimenez E.2
1Hospital Universitario Virgen de las Nieves, Medicina Preventiva y salud Publica, Granada, Spain, 2Hospital Universitario Virgen de las Nieves, Servicio Medicina Preventiva y salud Publica, Granada, Spain

PO11.05
Retrospective analysis of risks for travellers with underlying medical conditions
Wieten R.1, van Vugt M.1, Grobusch M.P.1
1Academic Medical Centre, Amsterdam, Netherlands

PO11.06
Applying Audience Feedback on Web-Based Travel Health Emergency Communications during the 2009 Influenza A (H1N1) Pandemic
Whatley A.D.1, Holton K.2, Urban N.3, Carera K.2, Jentes E.S.1, Brunette G.W.1
1Centers for Disease Control and Prevention, Travelers’ Health Branch, Division of Global Migration and Quarantine, Atlanta, United States of America, 2Oak Ridge Associated Universities, Health Communication and Technical Training, Oak Ridge, United States of America
PO11.07
*Imported Infectious Disease by Travellers in Spain: Results from the Spanish Network on Imported Infectious Diseases by travellers and Immigrants (+Redivi).*
1Hospital Universitario Ramón y Cajal, Madrid, Spain, 2CAP Drassanes, Barcelona, Spain, 3Hospital Universitario de Alicante, Alicante, Spain, 4Hospital 12 de Octubre, Madrid, Spain, 5Hospital Universitario de Guadalajara, Guadalajara, Spain, 6CAP Caramuel, Madrid, Spain, 7Hospital Universitario La Paz, Madrid, Spain, 8Hospital Infantia Sofía, Madrid, Spain, 9Complexo Hospitalario A Coruña, A Coruña, Spain

PO11.08
*Yellow fever queries from United Kingdom Yellow Fever Centres to a national travel health advice line*
1The National Travel Health Network and Centre, London, United Kingdom, 2Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 3London School of Hygiene and Tropical Medicine, London, United Kingdom

PO11.09
*CDCs Partnership Efforts to Reach Physicians and Patients with Travel Health Information*
1Travelers’ Health Branch, Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, United States of America, 2Logistics Health Incorporated, La Crosse, United States of America, 3Emergency Risk Communications Branch, Division of Emergency Operations, Centers for Disease Control and Prevention, Atlanta, United States of America, 4Medscape, New York, United States of America, 5WebMD, New York, United States of America, 6Public Health Television, Delray Beach, United States of America, 7Electronic Media Branch, Division of New and Electronic Media, Centers for Disease Control and Prevention, Atlanta, United States of America, 8Centers for Disease Control and Prevention, Atlanta, United States of America

PO11.10
*Assessing the Communication of Key Travel Health Messages: Media Coverage of CDC’s “Making the Case for Healthy Travel” Campaign*
Holton K., Whatley A.D., Hale S., Rhyne S.
1Centers for Disease Control and Prevention, Travelers’ Health Branch, Division of Global Migration and Quarantine, Atlanta, United States of America, 2Oak Ridge Associated Universities, Health Communication and Technical Training, Oak Ridge, United States of America, 3Ackermann Public Relations, Knoxville, United States of America

PO11.11
*Providing simple, credible health advice to travelers during the 2009 H1N1 pandemic: An evaluation of the “Making the Case for Healthy Travel” campaign*
Holton K., Whatley A.D., Carera K., Urban N., Hale S., Brunette G.W.
1Centers for Disease Control and Prevention, Travelers’ Health Branch, Division of Global Migration and Quarantine, Atlanta, United States of America, 2Oak Ridge Associated Universities, Health Communication and Technical Training, Oak Ridge, United States of America
PO11.12
*A preventable death?*
Willcox A.¹, Daniell K.², Allen J.³
¹A Talent 4 Health Ltd., Cheltenham, United Kingdom, ²Pavilion Travel Clinic, Gloucester, United Kingdom

PO11.13
*Online Survey on Knowledge about Risks, Prevention and Consequences of Infections with Hepatitis B Virus among Travellers from Four European Countries*
Herbinger K.-H.¹, Nothdurft H.D.¹, Prymula R.²
¹University of Munich, Tropical Medicine and Infectious Diseases, Munich, Germany, ²University of Hradec Kralove, University Hospital, Hradec Kralove, Czech Republic

PO11.14
*Trends in the knowledge, attitudes and practices of travelers towards prevention of hepatitis A: results from the Dutch Schiphol Airport Survey 2002-2009 with focus on risk groups*
van Genderen P.J.¹,², Fortanier A.C.², Kolkman S.W.³, Mulder P.G.⁴, Overbosch D.², Dutch Schiphol Airport Study Group
¹Institute for Tropical Diseases Rotterdam, Rotterdam, Netherlands, ²Travel Clinic Havenziekenhuis Rotterdam, Rotterdam, Netherlands, ³GlaxoSmithKline, Zeist, Netherlands, ⁴Erasmus University Rotterdam, Rotterdam, Netherlands

PO11.15
*Health risks encountered by Dutch medical students during an elective in the tropics and the quality and comprehensiveness of pre- and post-travel care*
Soonawala D.¹, Sharafeldin E.¹, Vandenbroucke J.P.², Hack E.³, Visser L.G.¹
¹Leiden University Medical Center, Department of Infectious and Tropical Diseases C5-P, Leiden, Netherlands, ²Leiden University Medical Center, Department of Clinical Epidemiology, Leiden, Netherlands, ³Leiden University Medical Center, Department of Student Affairs, Leiden, Netherlands

PO11.16
*Health Protection for travellers: Epidemiological analysis of frequent diseases and proposal of Training project for Tour Operator.*
Murer S.¹, Rizzato D.², Zamparo E.³, consentino M.⁴, gialdi C.⁴, Nicosia V.⁴
¹Az. ULSS n.8 Regione Veneto Asolo, Department of Prevention, Vidor (Treviso), Italy, ²Az. ULSS n.8 Regione Veneto Asolo, Asolo, Italy, ³ASL 6 Friuli Occidentale, Department of Prevention, Pordenone, Italy, ⁴Saipem S.p.A., QHSE/Saipem Med, san donato milanese, Italy

PO11.17
*Use of the National Travel Health Network and Centre website during a natural disaster: flooding in Pakistan 2010.*
Jermacane D.¹, Stillwell A.¹, Simons H.¹,², Wong C.S.¹,², Gawthrop M.¹, Lawrence J.³, Jones J.³, Hill D.R.¹,⁴
¹National Travel Health Network and Centre, London, United Kingdom, ²Liverpool School of Tropical Medicine, Liverpool, United Kingdom, ³Health Protection Agency, Travel and Migrant Health Section, Colindale, United Kingdom, ⁴London School of Hygiene and Tropical Medicine, London, United Kingdom

PO11.18
*If we know compliance is our Achille’s heel, why do we keep measuring it rather than trying to change it?*
Schofield S.¹, Tepper M.¹, Crane F.¹
¹Department of National Defence, Force Health Protection, Ottawa, Canada
PO11.19
Human immunodeficiency virus post-exposure prophylaxis for medical trainees on international rotations
Sarfaty S.1, Hamer D.H.1,2,3,4
1Boston University School of Medicine, Department of Medicine, Boston, United States of America, 2Boston University, Center for Global Health and Development, Boston, United States of America, 3Boston Medical Center, Section of Infectious Diseases, Boston, United States of America, 4Boston Medical Center, Travel Clinic, Boston, United States of America

PO11.20
Improving Travelers’ knowledge, decision-making, and adherence to malaria chemoprophylaxis: Examining the impact of incorporating the “Ottawa Malaria Decision Aid” into the pre-travel consultation process.
Ivory C.A.1, Levine J.2, Balfour L.2, McCarthy A.E.1,2
1University of Ottawa, Faculty of Medicine, Ottawa, Canada, 2Ottawa Hospital General Campus, Division of Infectious Diseases, Ottawa, Canada

PO11.21
Is risk assessment and teaching effective in reducing illness during the elective periods of medical students from Newcastle Medical School?
Schmid M.L.1,2, Smith K.3, Bradley P.2
1Royal Victoria Infirmary, Infection & Tropical Medicine, Newcastle upon Tyne, United Kingdom, 2University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, United Kingdom

PO11.22
Is international business travel bad for your heart health? A retrospective observational study
Hawkes M.1, Aw J.J.2
1University of Toronto, Institute of Medical Sciences, Toronto, Canada, 2Medcan Clinic, Toronto, Canada

Altitude, Driving, and Environmental Exposures

PO12.01
Awareness and Risk factors of Acute Mountain Sickness among travellers to Colombia, Equator, Bolivia and Peru: a cross-sectional study
Cavero Zamorano J.1, Gavaldà Mestre L.1, Masuet Aumatell C.1, Ramon Torrell J.M.1
1Hospital Universitari de Bellvitge, International Health Unit, Preventive Medicine department, L’Hospitalet de Llobregat, Spain

Occupational, Military and Airline Medicine

PO13.01
Pre Travel “Fitness to Fly” Evaluation in Travelers with Recent or Chronic Medical Problems
Smith R.L.1
1University of Washington School of Medicine, OB/GYN, Shoreline, United States of America

PO13.02
Travel Medicine and Occupational Health: important synergy
Nicosia V.1, Gialdi C.1, Consentino M.1, De Sanctis S.1
1Saipem S.p.A., QHSE/Saipem Med, San Donato Milanese, Italy
PO13.03
**Modalities of Overseas Repatriations of Patients: Reliability of Agreement between Coordinating Physicians**
Duchateau F.-X.¹, Verner L.¹
¹Mondial Assistance France SAS, Medical Department, Paris, France

PO13.04
**Prospective study of the epidemiology of infectious diseases and their predictors in Netherlands Armed Forces during deployment as part of EUFOR Chad/CAR**
Leenstra T.¹,², van Thiel P.P.¹,², Lensen J.H.M.³, Zeeuwen J.W.F.³, van Gool T.⁴, Kager P.A.¹
¹Academic Medical Center, Infectious Diseases, Tropical Medicine & AIDS, Amsterdam, Netherlands,
²Netherlands Ministry of Defence, the Hague, Netherlands, ³Royal Netherlands Navy, Den Helder,
Netherlands, ⁴Academic Medical Center, Medical Microbiology, section Parasitology, Amstendam, Netherlands

PO13.05
**Prevention and Management of Alcohol and Drugs use and abuse in an oil and gas company**
Nicosia V.¹, Consentino M.¹, Gialdi C.¹, Murer S.², Rizzato D.³, Zamparo E.⁴
¹Saipem S.p.A., QHSE/Saipem Med, san donato milanese, Italy, ²Az. ULSS n.8 Regione Veneto Asolo,
Department of Prevention, Vidor (Treviso), Italy, ³Az. ULSS n.8 Regione Veneto Asolo, Department of
Prevention, Asolo, Italy, ⁴ASL 6 Friuli Occidentale, Department of Prevention, Pordenone, Italy

**Trauma, Injury, Security**

PO14.01
**Envenoming By Sting-Ray Bites in French Guiana: Report of 8 Cases**
Bourée P.¹,², Tonnang G.², Joubert M.³
¹Paris XI University and Bicetre Hospital APHP, Tropical Diseases Dept, Kremlin-Bicetre, France, ²Health
Center, Maripasoula, French Guiana, ³Health Center, Direction, Cayenne, French Guiana

**Non-Infections Disease Travel Risks (e.g., Pulmonary Emboli, Jet Lag)**

PO15.01
**Cardiovascular risk among international travelers**
Chanudet X.¹
¹CMETE, Paris, France

**Professional Education and Training**

PO16.01
**E-learning in travel medicine - The Portuguese case study**
Fonseca A.G.¹, Dias S.S.¹, Gonçalves N.¹, Baptista J.L.¹, Torgal J.¹
¹Faculdade de Ciências Médicas, Public Health, Lisbon, Portugal

PO16.02
**Travel Health Knowledge among Taiwanese Tourism Industry Members on Travel Health and Infectious Disease**
Shih C.C.¹, Yang Y.-C.², Taiwan Association for International Health
¹National Cheng-Kung University Hospital, Department of Family Medicine, Tainan city, Taiwan, Republic
of China, ²National Cheng-Kung University, Department of Family Medicine College of Medicine, Tainan city,
Taiwan, Republic of China
PO16.03  
**The Challenges to Delivering Effective Travel Medicine Education in a Multi-disciplinary & Multi-state Health Care Corporation**  
McDevitt, RN, BSN, COHN-S S.A.¹, Kalish, MD S.¹  
¹Take Care Health Systems, Employers Solutions Group, New York, United States of America

PO16.04  
**A Survey of the ISTM Nurse Professional Group to assess members’ needs and identify areas for improvement**  
Chiodini J.¹, Grieve S.¹, Rosselot G.¹, Backer A.¹, Bosch J.¹, Hammer Boge R.¹, Rugsten C.¹, Kenney A.²  
¹Nurse Professional Group of the International Society of Travel Medicine, , United States of America, ²International Society of Travel Medicine, Secretariat, , United States of America

PO16.05  
**Travel Health Advisory Group: travel health promotion activities of a joint travel industry and travel health special interest group**  
Leggat P.A.¹, Hudson B.², Zwar N.³, Gherardin T.⁴, Cheng I.², Travel Health Advisory Group, Australia  
¹James Cook University, Anton Breinl Centre, Townsville, Australia, ²Royal North Shore Hospital, Sydney, Australia, ³University of New South Wales, School of Public Health and Community Medicine, Sydney, Australia, ⁴Travel Doctor, Melbourne, Australia

PO16.06  
**Survey of Immunisation Training Awareness in the United Kingdom**  
Ford L.¹,², Simons H.J.¹,², Wong C.S.¹,², Hill D.R.¹  
¹National Travel Health Network and Centre, London, United Kingdom, ²Liverpool School of Tropical Medicine, Liverpool, United Kingdom

PO16.07  
**Travel Health Nursing in the United States of America: A descriptive study of employment, education, and perceived professional challenges**  
Rosselot G.A.¹, Rosenblatt E.², Weinberg S.³, Acosta R.⁴, American Travel Health Nurses Association, USA  
¹Travel Well of Westchester, Inc, Briarcliff Manor, United States of America, ²University Hospital and Clinics, Internal Medicine Clinic, Madison, United States of America, ³Ridgefield Visiting Nurse Association, Ridgefield, United States of America, ⁴Traveler’s Medical Service, NY, United States of America
The 9th Asia Pacific Travel Health Conference, in conjunction with the 5th Regional Meeting of the International Society of Travel Medicine, will be held in Singapore from 2-5 May 2012.

The 4-day event will bring together travel medicine providers, clinicians, epidemiologists, researchers, vaccinologists, nurses and other practitioners from across Asia Pacific and the rest of the world. It offers a unique scientific program, focusing on a broad range of relevant topics and current emerging issues facing this fast-growing and dynamic region. Plenary sessions, concurrent symposium, meet-the-experts, workshops and debates will provide participants an opportunity to learn, exchange, and explore new ideas to improve their practice.

We welcome submissions of original, not previously published abstracts for oral and poster presentation. Visit www.apthc2012.org to submit your abstracts! Submission is open until 02 November 2011.
The 9th Asia Pacific Travel Health Conference, in conjunction with the 5th Regional Meeting of the International Society of Travel Medicine, will be held in Singapore from 2-5 May 2012.

The 4-day event will bring together travel medicine providers, clinicians, epidemiologists, researchers, vaccinologists, nurses and other practitioners from across Asia Pacific and the rest of the world. It offers a unique scientific program, focusing on a broad range of relevant topics and current emerging issues facing this fast-growing and dynamic region. Plenary sessions, concurrent symposium, meet-the-experts, workshops and debates will provide participants an opportunity to learn, exchange, and explore new ideas to improve their practice.

We welcome submissions of original, not-previously published abstracts for oral and poster presentation. Visit www.apthc2012.org to submit your abstracts! Submission is open until 02 November 2011.
For 20 years, ISTM has been at the forefront of the travel medicine community promoting safe and healthy travel on every continent. With more than 2,500 members in 75 countries, it is the largest organization of professionals dedicated to the advancement of the specialty of travel medicine.

In cooperation with national and international health care providers, academic centers, the travel industry and the media, ISTM advocates and facilitates education, communications, service and research activities in the field of travel medicine. This includes preventative and curative medicine within many specialties such as tropical medicine, infectious diseases, high-altitude physiology, travel-related obstetrics, psychiatry, occupational health, military, migration medicine and environmental health.

Members include physicians, nurses and other health professionals from academia, government and the private sector.

ISTM invites all who are interested in travel medicine to join and participate in the advancement of this field. Contact the ISTM Secretariat for more information.